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Breast cancer is the most common malignancy in women in the Western 
world and it is estimated that women who survive to the age of 85 years will 
have a 1 in 9 lifetime probability of developing this type of neoplasia (1, 2). 
The degree of risk is not spread homogeneously across the general population 
(2). The vast majority of risk factors associated to breast cancer susceptibility 
are related to hormonal exposure, either from endogenous sources such as 
early age at menarche, late age at menopause, late pregnancy or nullliparity, 
overweight and obesity, or exogenous sources such as the use of hormone 
replacement therapy (HRT) (3). Other risk factors include alcohol intake, 
radiation exposure, current age, past history of breast cancer and the history 
of a breast biopsy (2). Additionally, a recent study has shown that the risk of 
breast cancer is increased by 3% per pack/year of cigarette smoking when it is 
done between menarche and first childbirth (4).
1.1 Breast Cancer in The Netherlands
Breast cancer is the most common malignancy among Dutch women, ac-
counting for 34% of all cancers in women. The incidence of breast cancer in 
The Netherlands is one of the highest worldwide (6) and is estimated to be 
138/100,000 (7). Common risk factors in The Netherlands and other western 
countries which might explain the high incidence of this disease are late age 
at first full term pregnancy, tall stature and the high frequency of obesity (6, 
8). Due to the impact of breast cancer on public health, a population-based 
mammography-screening programme was started in the mid 1970’s in two 
Dutch regions (in and around the cities of Utrecht and Nijmegen) (9). From 
1989 onwards, nation-wide breast cancer screening was implemented in The 
Netherlands for all women aged between 50 and 69 years, and in 1998 it was 
broaden to incorporate women until age 75 years (9). This programme works 
in conjunction with the National Cancer Registry, which gives a national 
coverage since 1989 and is linked to the computerized national histopatho-
logical database (PALGA) (10). The records are complemented with clinical 
information by the regional Comprehensive Cancer Centers and checked for 
missing cases by comparing them to the national registry of outpatient and 
in-patient diagnoses (LMR) (11). These databases provide a comprehensive 
dataset readily available for researchers in the field.
One of the most important and consistent risk factors for the disease in 
the Netherlands and worldwide is a positive family history (12, 13). Breast 
cancer shows familial clustering (14) and twin studies show strong evidence 
for a genetic origin (15). For this reason, genetic screening of BRCA1 and 
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BRCA2 (the most important breast cancer predisposition genes) is becoming 
a routine exam in women with a family history of the disease (16). In the 
Netherlands the most frequent mutations in breast cancer patients under the 
age of 50 years is for the BRCA1 gene, which accounts for 2.8-6.9% (17) as 
compared to 4.6 % in other populations and 3.5-6.6% for BRCA2 as com-
pared to 3.5% in others (12, 16). There are a number of common founder 
mutations in the Netherlands including the IVS12-1643del3835 BRCA1 
mutation (17). In the Netherlands there are at least 10 screening centers for 
familial forms of breast cancer located throughout the country, comprising 
eight university hospitals and two cancer centers (18). BRCA1 and BRCA2 
mutation screening is performed when there is a history of at least three 
women with breast or ovarian cancer spread over at least two generations 
of the patient’s family (16). In Dutch women with a family history of breast 
cancer, the percentage of mutation carriers is estimated to be 6%. For women 
from families for whom no mutation in BRCA1/2 is identified but who have 
a family history of breast cancer, screening starts five years before the earliest 
age of onset of breast cancer in the family (19). The recent Dutch guidelines 
for surveillance of women with a familiar or genetic predisposition consist of 
a 6-monthly clinical breast examination, annual mammography and instruc-
tions for monthly breast self-examination (20). Nevertheless, the effectiveness 
of mammography screening in women under the age of 40 years is currently 
unproven, this is because pre-menopausal women have denser breasts which 
has been associated with a decreased sensitivity of mammography (21, 22). 
So, for premenopausal women, magnetic resonance imaging (MRI) is recom-
mended, a procedure that started in 1999 by The National Dutch study for 
MRI screening (MRISC) (20). In general, MRI appears to be more a sensitive 
screening method than mammography (overall sensitivity 71% vs. 40%), but 
less specific (overall specificity 90% vs. 95%) (19).
1.2 Genetics of breast cancer
Linkage analysis and positional cloning in the 1990s identified the BRCA1 
and BRCA2 susceptibility genes (13). In the general population approxi-
mately 1.6% of the women are expected to be carriers of BRCA1 and BRCA2 
mutations (23). In addition to these major genes, nine other can be consid-
ered well-established breast cancer susceptibility genes: TP53, PTEN, LKB1, 
ATM, NBS1, RAD50, BRIP1, PALB2 and CHEK2, but mutations in these 
are also extremely rare (13, 24). These genes have been estimated to account 
for 5-10% of the familial aggregation of this disease in which families have 
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at least 3 affected relatives, leaving the majority of the familiar breast cancer 
patients unexplained (2). In order to identify new breast cancer susceptibility 
genes one could apply two strategies, family and population based methods 
(25).
1.2.1 Family based methods
The most common approach to identify genes in family based studies is link-
age analysis. These studies are typically conducted in families with multiple 
cases of breast cancer. The basic principle is that if two or more genetic loci 
are in very close physical proximity, they are likely to segregate together in a 
pedigree (26). In linkage analysis, the hypothesis is that if the marker being 
tested and the disease gene are closely together they are segregating together 
during meiosis (27). There are two types of linkage approaches, parametric 
or model-dependent analysis, assuming a Mendelian pattern of segregation, 
and non-parametric linkage analysis which does not require a specification 
of the genetic model of inheritance and tests the sharing of marker alleles 
among pairs of relatives (27). Parametric linkage is the most powerful method 
for detecting linkage between a marker and disease when the model of in-
heritance can be correctly specified. Nevertheless, when the disease is complex 
and many genes can influence disease susceptibility, non-parametric linkage 
may be more accurate and powerful since model specification is not required 
(27).
Another, more specific type of linkage analysis is homozygosity mapping. 
Using this method, it is feasible to identify a recessive disease locus with only 
a very small number of patients derived from consanguineous marriages (28) 
or from genetically isolated populations where inbreeding is present.
1.2.2 Population-based methods
Although high penetrance genes have received the most attention, the search 
for low penetrance genes involved in breast cancer risk has acquired impor-
tance (29). Unlike the dominant effects of BRCA1 and BRCA2, these may 
show a complex inheritance (25). Segregation analyses suggest that a polygen-
ic model, may account for much of the residual genetic component of breast 
cancer susceptibility (13, 14, 25). The risk associated with any individual al-
lele may be small, but as the effects might be multiplicative, a woman with 
several susceptibility alleles may still be at high risk (14). The most powerful 
approach to find such variants is through association studies. These studies test 
the frequency of genetic variants in cases and controls and does not require 
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high-risk families (13). These variants may concern polymorphisms known to 
be causally related to the protein expression or disease risk (direct association 
studies) or randomly selected markers which may not be functional by them-
selves but may be in linkage disequilibrium with a causal variant (indirect as-
sociation studies). Classical association studies have targeted candidate genes, 
chosen by their potential involvement in carcinogenesis (13). A large number 
of candidate genes have been studied as shown in table 1.
Recent technological developments also genome-wide association studies, 
enable searches using single nucleotide polymorphisms (SNPs). Recently a 
large genome wide association (GWA) study was conducted including 21860 
cases and 22578 controls revealing evidence for association with breast cancer 
for five new loci (FGFR2, TNRC9, MAP3K1, LSP1 and an unknown locus 
on chromosome 8q) (30). The risks associated with these single genes are small 
Table 1. Candidate genes studied in relation to Breast Cancer in at least 3 studies
Gene
No 
studies Polymorphism Gene
No 
Studies Polymorphism Gene
No 
Studies Polymorphism
Andro. R. 3 CAG repeat Hsd17b1 3 Ser-Gly(A->G) TGF Beta 9 Leu10Pro
APO E 3 E4 allele IGF1 6 CA n repeat TNF alpha 5 G-308A
CCND1 4 G870A IGFBP3 3 A(-202)C UDP 1A1 3 TA repeat
COMT 18 Val158Met ITGB3 3 Leu33Pro VDR 7 BsmI RFLP
CYP 1B1 7 Leu432Val IL-6 3 G(-)174C VDR 5
Taq1 ATT-ATC 
silent
CYP 1B1 4 Ala119Ser MDM2 3 T309G VDR 5 Fok var length
CYP 1B1 3 N453Ser MMP3 3 5A/6A VDR 3 PolyA var length
CYP17 17 T(-34)C MnSOD 7 Ala9Val VDR 3 RFLP ApaI
CYP19 11 TTTA n repeat NAT1 4 *11 VEGF 4 C936T
CYP1A1 16 m1 (MspI) NAT2 19 3 polymorphisms XPD 9 Lys751Gln
CYP1A1 13 m2 A2455G NBS1 4 E185Q XPD 7 Asp312Asn
CYP1A1 5 m4 C2453A NQO1 3 Pro187Ser XRCC1 4 Arg280His
ER Alpha 7 PvuII p53 7 Arg72Pro XRCC2 5 Arg188His
ER Alpha 6 XbaI p53 5 Intron 6 Msp G>A XRCC3 9 Thr241Met
ER Alpha 3 A594G p53 5 Intron 3 16bp
GPX1 3 Pro198Leu Prog. Re. 3 G331A
GSTM1 30 I/D Prohibitin 4 C39T
GSTP1 9 Ile105Val RAD 51 4 G135C
GSTT1 21 I/D SRD5A2 3 Val89Leu
HER2 13 Val655Ile STK15 4 Val57Ile
HOGG1 4 Ser326Cys SULT1A1 11 Arg213His
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and vary from a relative risk of 1.17 for the LSP1gene to 1.63 for the FGFR2 
gene. Combining the effect of all 4 genes assuming a multiplicative model 
explains an estimated 3.6% of the excess risk of breast cancer (population 
attributable risk) in patients with a family history of the disease (30), leaving 
the vast majority of the genetic risk for breast cancer still unexplained.
1.3 Study design
In this thesis, we conducted a series of population-based studies using the 
principle of association. We chose for this approach because a polygenic 
model of inheritance appears to underlie the disease in the majority of pa-
tients who cannot be explained by the high penetrance mutations known to 
date (23). Although the advantage of case-control studies embedded in the 
Netherlands Cancer registry is that one can ascertain rapidly a large number 
of patients in whom the diagnosis is well defined, a draw back of this design 
is that mortality may occur related to the gene under study which may bias 
findings. A further practical problem is the selection of age, sex and region 
matched controls, which asks for an extensive time investment. Within the 
Erasmus MC, there is an ongoing follow-up study, the Rotterdam study; The 
Rotterdam Study is a prospective cohort study that started in 1991, in which 
determinants of disease are studied (31). The baseline cohort comprises par-
ticipants age 55 years and older. We have chosen to embed our studies of 
breast cancer within the Rotterdam Study since the prospective design al-
lowed us to rapidly study genes in breast cancer patients in whom no selection 
due to early survival occurred, at least for the incident patients. The limitation 
of embedding the study in the Rotterdam Study is that we can only study 
late-onset, post-menopausal, disease. Further, the mortality in the incident 
patients is still very low, which prevents us from studying genes in relation to 
breast cancer survival.
We used three different databases for breast cancer case identification. 
First, cases diagnosed by general practitioners in the research area (Ommoord, 
a suburb of Rotterdam where the study is set) were collected following the 
International Classification of Primary Care (X76)). Second, the Dutch 
National Registry of all hospital admissions (LMR) was consulted to detect 
all malignancy related hospital admissions from study participants. Finally, 
regional pathology databases were linked to the Rotterdam Study to identify 
cases. Subsequently, a physician on the basis of medical records of the general 
practitioner, discharge letters and pathology reports validated breast cancer 
cases. Only pathologically confirmed cases were considered in the analysis.
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The selection of the candidate genes studied in this thesis was based on 
the biological plausibility of their involvement in different carcinogenic pro-
cesses such as neovascularization and growth promotion, inflammation and 
estrogen response. As to the marker selection, we target specifically markers, 
which were known to have functional effects on the protein level. Basically, 
we are following an approach also referred to as Mendelian Randomization. 
According to this principle, the random assortment of genes from parents 
to offspring that occurs during gamete formation and conception provides 
one method for assessing the causal nature of exposures. In this sense, the 
association between a disease and a polymorphism that mimics the biological 
link between a proposed exposure (the protein under study) and disease is not 
generally susceptible to the reverse causation or confounding that may distort 
interpretations of conventional observational studies (32).
1.4 Outline of the thesis
This thesis aimed at studying the effect of functional variants in a series of 
candidate genes on the risk of breast cancer.
These population-based studies were carried out in the Rotterdam Study 
and the candidate genes were selected according to their relevance in different 
oncogenic processes.
Chapter 2 and 3 explore the possible association of renin angiotensin sys-
tem (RAS) polymorphisms and breast cancer risk since Angiotensin II has 
been proven to be a potent angiogenic factor (33). Angiogenesis or neovascu-
lar formation is an important mediator of cancer development and progres-
sion since it permits sustained tumor growth and mediates metastasis (34). 
Chapters 4 and 5 evaluate the relationship of two genes involved in inflamma-
tory processes including interleukin-6 (IL-6) and transforming growth factor 
β1 (TGF-β1). The inflammatory pathway is important in breast carcinogen-
esis since it can induce genetic alterations that initiate tumorigenesis (35). 
We studied the effect of a genetic variant in the insulin-like growth factor-I 
(IGF-I) promoter in Chapter 6. IGF-1 is an important growth factor and 
its levels have been associated to premenopausal breast and prostate cancer. 
Finally, since estrogen has been recognized for long as a major precursor of 
breast cancer pathogenesis, Chapter 7 studies the association between two 
polymorphisms in the estrogen receptor (ESR1) gene and the risk for breast 
cancer. Finally Chapter 8 presents the general discussion of this thesis.
Introduction 
17
References
 1. Gayther SA, Pharoah PD, Ponder BA. The genetics of inherited breast cancer. J 
Mammary Gland Biol Neoplasia 1998;3(4):365-76.
 2. Singletary SE. Rating the risk factors for breast cancer. Ann Surg 2003;237(4): 
474-82.
 3. Hulka BS, Moorman PG. Breast cancer: hormones and other risk factors. Ma-
turitas 2001;38(1):103-13; discussion 113-6.
 4. Ha M, Mabuchi K, Sigurdson AJ, Freedman DM, Linet MS, Doody MM, et 
al. Smoking cigarettes before first childbirth and risk of breast cancer. Am J 
Epidemiol 2007;166(1):55-61.
 5. Wobbes T, Nortier, JWR, Koning CCE. Handboek Mammacarcinoom: de 
Tijdstroom; 2007.
 6. Visser O, van der Kooy K, van Peppen AM, Ory FG, van Leeuwen FE. Breast 
cancer risk among first-generation migrants in the Netherlands. Br J Cancer 
2004;90(11):2135-7.
 7. Sant M, Francisci S, Capocaccia R, Verdecchia A, Allemani C, Berrino F. Time 
trends of breast cancer survival in Europe in relation to incidence and mortality. 
Int J Cancer 2006;119(10):2417-22.
 8. van den Brandt PA, Dirx MJ, Ronckers CM, van den Hoogen P, Goldbohm 
RA. Height, weight weight change, and postmenopausal breast cancer risk: The 
Netherlands Cohort Study. Cancer Causes Control 1997;8(1):39-47.
 9. Fracheboud J, de Koning HJ, Boer R, Groenewoud JH, Verbeek AL, Broeders 
MJ, et al. Nationwide breast cancer screening programme fully implemented in 
The Netherlands. Breast 2001;10(1):6-11.
 10. Casparie M, Tiebosch AT, Burger G, Blauwgeers H, van de Pol A, van Krieken 
JH, et al. Pathology databanking and biobanking in The Netherlands, a central 
role for PALGA, the nationwide histopathology and cytopathology data net-
work and archive. Cell Oncol 2007;29(1):19-24.
 11. Fracheboud J, Otto SJ, van Dijck JA, Broeders MJ, Verbeek AL, de Koning HJ. 
Decreased rates of advanced breast cancer due to mammography screening in 
The Netherlands. Br J Cancer 2004;91(5):861-7.
 12. Thompson D, Easton D. The genetic epidemiology of breast cancer genes. J 
Mammary Gland Biol Neoplasia 2004;9(3):221-36.
 13. Antoniou AC, Easton DF. Models of genetic susceptibility to breast cancer. 
Oncogene 2006;25(43):5898-905.
 14. Pharoah PD, Antoniou A, Bobrow M, Zimmern RL, Easton DF, Ponder BA. 
Polygenic susceptibility to breast cancer and implications for prevention. Nat 
Genet 2002;31(1):33-6.
Chapter 1
18
 15. Lichtenstein P, Holm NV, Verkasalo PK, Iliadou A, Kaprio J, Koskenvuo M, 
et al. Environmental and heritable factors in the causation of cancer--analyses 
of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med 
2000;343(2):78-85.
 16. van der Hout AH, van den Ouweland AM, van der Luijt RB, Gille HJ, Bod-
mer D, Bruggenwirth H, et al. A DGGE system for comprehensive mutation 
screening of BRCA1 and BRCA2: application in a Dutch cancer clinic setting. 
Hum Mutat 2006;27(7):654-66.
 17. Verhoog LC, van den Ouweland AM, Berns E, van Veghel-Plandsoen MM, 
van Staveren IL, Wagner A, et al. Large regional differences in the frequency of 
distinct BRCA1/BRCA2 mutations in 517 Dutch breast and/or ovarian cancer 
families. Eur J Cancer 2001;37(16):2082-90.
 18. Hopwood P, van Asperen CJ, Borreani G, Bourret P, Decruyenaere M, Dishon 
S, et al. Cancer genetics service provision: a comparison of seven European 
centres. Community Genet 2003;6(4):192-205.
 19. Kriege M, Brekelmans CT, Boetes C, Besnard PE, Zonderland HM, Obdeijn IM, 
et al. Efficacy of MRI and mammography for breast-cancer screening in women 
with a familial or genetic predisposition. N Engl J Med 2004;351(5):427-37.
 20. Kriege M, Brekelmans CT, Boetes C, Rutgers EJ, Oosterwijk JC, Tollenaar 
RA, et al. MRI screening for breast cancer in women with familial or genetic 
predisposition: design of the Dutch National Study (MRISC). Fam Cancer 
2001;1(3-4):163-8.
 21. Kerlikowske K, Grady D, Barclay J, Sickles EA, Ernster V. Effect of age, breast 
density, and family history on the sensitivity of first screening mammography. 
Jama 1996;276(1):33-8.
 22. Kriege M, Brekelmans CT, Obdeijn IM, Boetes C, Zonderland HM, Muller 
SH, et al. Factors affecting sensitivity and specificity of screening mammogra-
phy and MRI in women with an inherited risk for breast cancer. Breast Cancer 
Res Treat 2006;100(1):109-19.
 23. Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-
based series of breast cancer cases. Anglian Breast Cancer Study Group. Br J 
Cancer 2000;83(10):1301-8.
 24. Walsh T, King MC. Ten genes for inherited breast cancer. Cancer Cell 2007; 
11(2):103-5.
 25. Struewing JP. Genomic approaches to identifying breast cancer susceptibility 
factors. Breast Dis 2004;19:3-9.
 26. Iau PT, Macmillan RD, Blamey RW. Germ line mutations associated with 
breast cancer susceptibility. Eur J Cancer 2001;37(3):300-21.
 27. Foroud T. Introduction to genetic linkage analysis. Cancer Invest 1997;15(6): 
548-52.
Introduction 
19
 28. Lander ES, Botstein D. Homozygosity mapping: a way to map human recessive 
traits with the DNA of inbred children. Science 1987;236(4808):1567-70.
 29. Armstrong K. Genetic susceptibility to breast cancer: from the roll of the dice 
to the hand women were dealt. Jama 2001;285(22):2907-9.
 30. Easton DF, Pooley KA, Dunning AM, Pharoah PD, Thompson D, Ballinger 
DG, et al. Genome-wide association study identifies novel breast cancer suscep-
tibility loci. Nature 2007;447(7148):1087-93.
 31. Hofman A, Grobbee DE, de Jong PT, van den Ouweland FA. Determinants of 
disease and disability in the elderly: the Rotterdam Elderly Study. Eur J Epide-
miol 1991;7(4):403-22.
 32. Davey Smith G, Ebrahim S. ‘Mendelian randomization’: can genetic epidemi-
ology contribute to understanding environmental determinants of disease? Int 
J Epidemiol 2003;32(1):1-22.
 33. Walther T, Menrad A, Orzechowski HD, Siemeister G, Paul M, Schirner M. 
Differential regulation of in vivo angiogenesis by angiotensin II receptors. Faseb 
J 2003;17(14):2061-7.
 34. Mandic A, Vujkov T, Novakovic P, Komazec S. Tumor angiogenesis in gyneco-
logical oncology. J Buon 2002;7(1):19-23.
 35. Radisky ES, Radisky DC. Stromal induction of breast cancer: Inflammation 
and invasion. Rev Endocr Metab Disord 2007.

Chapter 2
Angiotensin Converting Enzyme Gene 
Insertion/Deletion Polymorphism and 
Breast Cancer Risk
AM González-Zuloeta Ladd, A Arias Vásquez, FA Sayed-Tabatabaei, JW Coebergh, A 
Hofman, O Njajou, B Stricker, CM van Duijn. Cancer Epidemiol Biomarkers Prev. 
2005 Sep;14:2143-6.
Chapter 2
22
Abstract
The Renin-Angiotensin system plays an important role in homeostasis and 
lately, its main effector, Angiotensin II has been attributed with angiogenic 
and growth factor actions in the breast tissue. Previous studies have shown 
that the Insertion/Deletion polymorphism in the ACE gene accounts for the 
variability of ACE plasma concentrations. The use of ACE inhibitors and the 
ACE I/D polymorphism may be linked to breast cancer risk. In this study we 
evaluate the relationship of the ACE I/D polymorphism with breast cancer 
risk in Caucasian postmenopausal women. The ACE I/D polymorphism was 
genotyped in 4117 women participants in the Rotterdam Study. Baseline 
information was obtained through a questionnaire. We conducted a logistic 
regression and survival analysis to assess the risk of breast cancer by ACE 
genotype. The DD carriers showed a significantly increased risk of develop-
ing breast cancer when compared to the II carriers (OR = 1.86, 95% CI = 
1.06-3.27, p-value = 0.03). This association remained after adjusting for other 
risk factors, including, BMI, age at menarche, age at menopause, HRT and 
hypertension. Our survival analysis showed that the cancer free survival was 
significantly reduced in DD compared to II carriers (OR = 1.80; 95% CI: 
1.07-3.01, p-value = 0.03). Our results suggest that the ACE I/D polymor-
phism plays an important role in breast cancer risk and disease free survival in 
Caucasian postmenopausal women.
Angiotensin Converting Enzyme Gene Insertion/Deletion Polymorphism
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Introduction
Breast cancer presents a serious public health risk in both developed and 
developing countries. With one million new cases diagnosed in the world 
annually, it accounts for 18% of all female malignancies (1, 2). Risk factors 
for this disease vary from lifestyle to genetic factors (3), which are estimated to 
account for 15-25% of the cases (4). Germline mutations in high penetrance 
genes such as BRCA 1 and 2, explain less than 5% of all breast cancer cases 
(4). Most likely, the genetic susceptibility to breast cancer is explained by 
multiple highly penetrant mutations and a larger number of low penetrance 
mutations (5). The genes involved in breast cancer are expected to be respon-
sible for key processes in cell growth regulation and cell proliferation includ-
ing angiogenesis (6). One of the newly studied angiogenic and growth factors 
is Angiotensin II (7), which has a wide spectrum of target tissues including 
breast epithelial cells. It has a variety of functions, acting as a growth factor 
both in normal and cancer epithelial breast cells and promoting angiogenesis 
(7, 8). Angiotensin II is converted from Angiotensin I by the Angiotensin-
converting enzyme (ACE). Studies conducted to assess the role of ACE and 
ACE inhibitors in both breast cancer and cancer in general show contradict-
ing results. Whereas ACE inhibitors have been shown to block the processes 
of angiogenesis and tumor growth both in vivo and in vitro (9, 10), findings 
on the protective effect of ACE inhibitors on cancer still remain inconsistent. 
While Lever et al (1998) (11) found a decreased risk of cancer in patients 
taking ACE inhibitors, Li et al (2003) (12), Friis et al (2001) (13) showed no 
protective effect of these drugs. An alternative way to study the role of ACE 
in cancer is to study the gene encoding for this enzyme. The ACE gene, which 
is located in chromosome 17q23, has many polymorphisms. The most com-
monly studied is a 287-bp Alu insertion/deletion (I/D) polymorphism in in-
tron 16 that accounts for 50% of the variability in circulating ACE levels (14-
16) and has been shown to be in complete LD with the putative ACE linked 
QTL in Caucasians (15, 16). Furthermore, Koh et al (2003) (17) showed that 
Chinese women who carried the I allele of the ACE I/D polymorphism had 
lower risk of developing breast cancer.
In this study we evaluated the relationship of the I/D polymorphism in 
the ACE gene to breast cancer risk in a population-based study of Caucasian 
postmenopausal women.
Chapter 2
24
Patients and Methods
Study Population
Our study is part of the Rotterdam Study, a population-based follow-up study 
of determinants of diseases in the elderly. All inhabitants of Ommoord, a sub-
urb of Rotterdam, aged 55 years or older were invited to participate, of whom 
7983 agreed (78.1%). The design of the study has been previously described 
(18). From all subjects, informed consent was obtained and the Medical Eth-
ics Committee of the Erasmus Medical Center approved the study. The study 
population consisted of all 4878 female postmenopausal participants.
Measurements
At baseline, information concerning age, smoking behavior, parity and num-
ber of children, hormone replacement therapy, age at menopause and medical 
history was obtained by an interview (18). Body Mass Index (BMI) was cal-
culated by dividing the weight in kilograms by the height (in meters) squared 
(19). Blood pressure measurement has been previously described (20).
Cancer Diagnosis
General Practitioners (GP) reported the cases through a computer system 
covering 80% of the study population. For those participants not covered, 
research physicians visit GPs to record all morbidity. Finally to acquire a 
complete ascertainment, histologically confirmed breast cancer diagnoses 
and incidence dates were obtained from the discharge registries of all hospi-
tals in Rotterdam, the Daniel den Hoed cancer clinic and PALGA (Patho-
logical Anatomical District Automatized Archives)(21), a Dutch nation-wide 
network and registry of histo- and cytopathology. Furthermore, a biannual 
screening mammography was implemented in 1991 for women aged 50 to 
69 years and since 1998 also for women 70 to 74 years (22).All diagnoses 
until February 2003, both in situ and invasive carcinomas, were included in 
the analyses.
Genotyping
The ACE Insertion/Deletion (I/D) polymorphism was genotyped in 4117 
(89.4%) of the women in the Rotterdam Study (84.4%). DNA was isolated 
from blood samples using standard procedures (salting out method) (23). The 
II, ID and DD genotypes were detected by using the polymerase chain reac-
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tion technique (PCR) according to the method of Lindpainter et al (24) with 
modifications. The genotype procedure has been already described (25).
Data Analysis
Hardy-Weinberg equilibrium (HWE) of the I/D polymorphism was tested 
using Markov-Chain Monte-Carlo approximation of the exact test, as imple-
mented in the GENEPOP package V 3.3 (26). Categorical variables (parity, 
hormone replacement therapy (HRT), smoking, antihypertensive drug use 
and ACE inhibitors use) were compared between genotype groups using the 
chi-squared test. Continuous variables, which were not normally distributed, 
(age at entry, age at menopause and BMI) were compared using the indepen-
dent sample Mann-Whitney test. We conducted the analysis in two steps. 
Firstly, we used logistic regression to study the risk of breast cancer by ACE 
genotype. We adjusted for possible confounders such as age at entry, age at 
menopause, and we stratified for parity, HRT, smoking, antihypertensive 
drug use and BMI, generating five models. Secondly and in order to calculate 
disease free survival by ACE genotype, a Cox proportional hazards model was 
fitted using age as the underlying time of the model and taking the II genotype 
as the reference category. Further stratification was done by parity, HRT and 
BMI, to study interactions between the gene and other risk factors associated 
with breast cancer. The covariates used in both analyses were used because of 
their well-documented importance as risk factors for breast cancer (11, 12, 
27-29) or their association with genotype (20, 25). Logistic regression analysis 
was performed using SPSS for windows software package version 11.0 and 
the survival analyses were carried out using the S-plus program version 6.
Results
Of a total of 4878 postmenopausal women included in our study, 4117 
(84.4%) were successfully genotyped. Of these women 8.1 % were lost to 
follow up. Loss of follow up was not associated with ACE genotype or to 
risk factors for breast cancer. The frequencies of the I/D genotypes of the 
ACE gene were in Hardy-Weinberg equilibrium proportions (p = 0.96). The 
distribution of the studied variables was not significantly different between 
genotypes (Table 1). The distribution of ACE inhibitor use between geno-
types was not different across genotypes (data not shown).
There were 87 (2.1%) women who entered the study with previously di-
agnosed breast cancer and 114 (3.4%) were diagnosed during follow-up. The 
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prevalent cases were excluded from all analyses. The number of breast cancer 
cases by genotype is shown in Figure 1. The figure shows that the number 
of breast cancer patients increases as the number of D alleles increases (p for 
trend = 0.02).
The logistic regression yielded an OR = 1.86 (95% CI: 1.06-3.27, p = 
0.03) for DD carriers. Further adjustment of this model for HRT produced 
the same results. Adjustment for antihypertensive drug use provided an 
Table 1. General Characteristics of the study population stratified by ACE I/D 
genotype
Genotype DD ID II Overall
Total Studied (%) 1170 (28.4%) 2247 (49.7%) 900 (21.9%) 4117
Mean Age of Entry (SD) 70.49 (9.82) 70.48 (9.54) 69.48 (9.80) 71.65 (10.27)
Mean Age at Death 83.93 (9.41) 84.45 (8.51) 84.05 (8.62) 84.20 (8.81%)
Mean Age at Menopause (SD) 48.76 (5.23) 48.9 (5.04) 48.72 (5.27) 48.88 (5.2)
Mean Number of Children 2.06 (1.73) 2.09 (1.69) 2.17 (1.76) 2.10 (1.71)
Parity (%) (≥ 1 child) 885 (78.3%) 1562 (79.3%) 683 (79.3%) 64.17 (76.03%)
Hormone Replacement
Therapy (%)
126 (10.8%) 220 (10.7%) 105 (11.7%) 451 (10.95%)
Use of Anti-Hypertensives 160 (13.9%) 257 (12.8%) 98 (11.1%) 515 (12.8%)
Hypertension (%) 430 (36.8%) 752 (36.7%) 299 (33.2%) 1481 (35.97%)
Mean Body Mass Index (SD) 26.791 (4.12) 26.667 (4.12) 26.729 (4.02) 26.71 (4.09)
Current Smokers (%) 181 (15.55%) 351 (17.1%) 171 (19%) 433 (10.52%)
All p values ≥ 0.05
Figure 1. Frequency of Breast cancer cases by Genotype.
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OR = 1.90 (95% CI: 1.06-3.27, p=0.3) for DD vs II carriers. This association 
remained significant when additionally adjusting for parity (OR = 1.79; 95% 
CI: 1.06-3.27, p-value = 0.03), smoking (OR = 1.83; 95% CI: 1.04-3.21, 
p-value = 0.03) and BMI (OR = 2.06; 95% CI: 1.14-3.71, p-value = 0.02). 
Hazard Ratios for breast cancer risk for the DD and ID genotypes are shown 
in table 2. In our first model we used age as the underlying time of the model 
and adjusted for age at menopause. By age 90 years, 4% of the DD carriers 
had developed breast cancer compared to 2.3% of II carriers and 2.8% of 
ID carriers. This translates into a hazard ratio for breast cancer of 1.80 (95% 
CI: 1.07-3.01, p-value = 0.026) for DD, which is maintained at all ages (fig-
ure 2).
Figure 2. Cancer Free Survival by ACE I/D Genotype
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Table 2. Hazard Ratios for Breast Cancer by Genotype
Breast Cancer Risk adjusted by Age at Menopause and stratified by HRT
N II ID DD
All 3724 ref 1.23 (0.75-2.03) 1.80 (1.07-3.01)*
No use HRT 3280 ref 1.60 (0.90-2.84) 2.13 (1.18-3.86)*
Use HRT 444 ref 0.25 (0.07-.913)* 0.79 (0.26-2.42)
*=p-value<0.05
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Discussion
We conducted an association study to evaluate the relationship between the 
ACE I/D polymorphism and the risk of breast cancer, and we did so in two 
steps. Our analysis showed that DD carriers have an increased risk of devel-
oping breast cancer. When analyzing this group, all further adjusted models 
showed significantly increased risks for DD carriers when compared to II 
carriers. We also report a linear increase of breast cancer risk with the presence 
of the D allele of I/D polymorphism in the ACE gene.
For premenopausal women the BRCA 1 and 2 genes have been associated 
with an increased risk for breast cancer (5, 27, 30-32). A vast literature sug-
gests that variants in genes that regulate cell growth are involved in the devel-
opment of this disease (5, 33). Moreover, several studies have shown that An-
giotensin II acts as a growth factor in normal and breast cancer cells through 
phospholipase C activation (8, 34-37). Koh et al (2003) (17) conducted a 
study among Chinese postmenopausal women in which they found that in-
dividuals carrying the II genotype had a significantly reduced risk of breast 
cancer independently of environmental and other familial risk factors for the 
disease. On the other hand, Haiman et al (38) performed a case-control study 
in a multiethnic cohort where they observed a modest positive association 
between the II genotype and breast cancer risk in African Americans. They 
did not, however, see the association consistently in all ethnic groups. Fur-
thermore, although they had a large sample within each ethnic group, it was 
not large enough to evaluate ethnic specific risks, and their patients included 
both pre and postmenopausal women.
A large number of polymorphisms are known in the ACE gene. Here 
we only tested the ACE I/D polymorphism in intron 16. It has been previ-
ously reported that in a subset of our population, this polymorphism explains 
around 28% of the variability of plasma ACE levels (39). Furthermore, this 
polymorphism is in strong linkage disequilibrium with the functional ones in 
this gene, as measured as the relation to ACE levels or cardiovascular disease 
outcomes (15, 16). The strong linkage disequilibrium implies that testing ad-
ditional markers will yield little extra information.
So far and to our knowledge, no follow-up study has been performed to 
assess breast cancer free survival by ACE I/D genotype. Our study is the first 
to investigate the risk of breast cancer longitudinally, and find that it was sig-
nificantly increased in DD versus II carriers independently of all our proposed 
known risk factors. HRT and parity did not weaken our association between 
the I/D polymorphism and breast cancer risk.
Angiotensin Converting Enzyme Gene Insertion/Deletion Polymorphism
29
Our results suggest that the ACE I/D polymorphism may play an impor-
tant role as susceptibility factor in breast cancer risk and disease free survival 
in Caucasian postmenopausal women.
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Abstract
While angiotensinogen (AGT) seems to have anti proliferative properties, an-
giotensin II (ATII) is a potent growth factor and it mediates its actions through 
the angiotensin type 1 receptor (AGTR1). In the AGT gene, the M235T 
polymorphism has been associated with the variation in angiotensinogen 
levels and in the AGTR1 gene; the C573T variant is associated with differ-
ent pathologies. We aimed to evaluate the relationship of these two variants 
and the risk of breast cancer. These polymorphisms were genotyped in 3787 
women participating the Rotterdam Study. We performed a logistic regression 
and a disease free survival analysis by genotype. The logistic regression yielded 
an odds ratio of 1.4 (95% CI: 1.1-1.9) for the MM genotype carriers vs. the 
T allele carriers. The breast cancer free survival by AGT genotype was signifi-
cantly reduced in MM genotype carriers compared to non-carriers (hazard 
ratio (HR) = 1.5; 95% CI: 1.1-2.2). We did not find any association of the 
AGTR1 polymorphism and breast cancer risk or disease free survival. Our 
results suggest that AGT plays a role in breast cancer risk in postmenopausal 
women, whereas the role of AGTR1 needs further studying.
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Introduction
Breast cancer is a major cause of morbidity and mortality among women 
worldwide especially in middle age (1) and growth factors have been found 
to play an important role in the etiology and progression of this disease (2). 
Several proteins of the Renin-Angiotensin-Aldosterone system (RAS) have 
been implicated in the processes of growth promotion or inhibition (3-6) 
and are found present both in normal and cancerous breast tissues (7, 8). We 
have previously reported an association between the angiotensin-converting-
enzyme (ACE) I/D polymorphism and breast cancer risk in postmenopausal 
women. The DD carriers were at a higher risk for the disease (9). This finding 
has prompted us to study other genes involved in the RAS system influencing 
the angiotensin II pathway.
Angiotensin II (ATII) has been proven to have growth factor and angio-
genic activities (3, 7) and these activities are mediated through the activa-
tion of the angiotensin type 1 receptor (AGTR1) (8, 10). On the contrary, 
angiotensinogen (AGT) may have antiproliferative properties (6). Due to 
these distinct properties of different members of the same pathway on cell 
proliferation, the relationship between AGT and breast cancer risk remains 
to be clarified. An increase in AGT could either benefit women because of its 
antiproliferative properties; but on the other hand increase the risk for breast 
cancer since higher levels of AGT translate into a raise in ATII (11) with its 
growth factor and angiogenic activities .
There are many polymorphisms in the AGT gene located on chromosome 
1q42-q43. In exon 2, a non-synonymous substitution of T by C in codon 
235 of the AGT gene, leads to a change from Methionine to Threonine. In 
Caucasians, African and Japanese populations (6, 12-18) the T235 variant 
of this M235T polymorphism of this gene has been consistently associated 
with higher levels of angiotensinogen in plasma and an increased risk for 
hypertension (19). In the AGTR1 gene, also various polymorphisms have 
been recently studied (20-23). A T to C substitution at codon 573 has been 
found to be significantly more frequent in myocardial infarction cases (19) 
and microalbuminuria in hypertensive patients (20). These two AGT and 
AGTR1 polymorphisms have not been studied in relation to the risk for 
breast cancer.
In this study we aim to examine the relationship of the AGT M235T and 
the AGTR1 C573T polymorphisms and the risk of breast cancer in Cauca-
sian postmenopausal women.
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Patients and Methods
Study Population
Our study population is part of the Rotterdam Study, a population-based 
follow-up study of determinants of diseases in the elderly. All inhabitants of 
Ommoord, a suburb of Rotterdam, aged 55 years or older were invited to par-
ticipate. The design of the study has been previously described (24). From all 
subjects, informed consent was obtained and the Medical Ethics committee 
of the Erasmus Medical Center approved the study. Out of 7.983 participants 
(response rate of 78%) who were examined at baseline (1990 to 1993), 4878 
(61.1%) were women.
Measurements
At baseline, information concerning age, smoking, parity and number of chil-
dren, hormone replacement therapy, age at menarche and menopause, medi-
cation use and medical history was obtained by a standardized interview (24). 
Body mass index (BMI) was calculated by dividing the weight in kilograms by 
the height (in meters) squared (25).
Case Identification and Validation
Three different databases were used for case identification. First, cases diag-
nosed by general practitioners in the research area (Ommoord) were collected 
(International Classification of Primary Care (X76)). Second, the Dutch 
National Registry of all hospital admissions (LMR) was consulted to detect 
all malignancy related hospital admissions for study participants. Finally, re-
gional pathology databases were linked to the Rotterdam Study to identify 
cases. Subsequently, breast cancer cases were validated by a physician on the 
basis of medical records of the general practitioner, discharge letters and pa-
thology reports. Only pathologically confirmed cases were considered in the 
analysis. The index date was defined as the earliest date found in the pathol-
ogy report.
Genotyping
The AGT M235T and AGTR1 C573T polymorphisms were successfully 
genotyped in 3527 (73%) and 3787 (78%) postmenopausal women in the 
Rotterdam Study. DNA was isolated from blood samples using standard pro-
cedures (salting out method) (26) . The M and T alleles of the AGT gene were 
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identified using a set of oligonucleotide primers flanking the polymorphic site 
in exon 2 (forward primer, 5’CTG GCT CCC ATC AGG3’, reverse primer, 
5’CTG GCT CCC GTC AGG3’). Likewise, the C and T alleles were de-
tected using a set of oligonucleotide primers flanking the polymorphic site in 
exon 5 (forward primer 5’-CAA AGT CAC CTG CAT CAT CA-3’, reverse 
5’ –AGG AAA CAG GAA ACC CA3’(19).
Data Analysis
Hardy-Weinberg equilibrium proportions (HWE) of the AGT M235T and 
AGTR1 C573T polymorphisms were tested using Markov-Chain Monte-
Carlo approximation of the exact test, as implemented in the GENEPOP 
package V 3.3 (27). Categorical variables (parity, hormone replacement ther-
apy (HRT), smoking, antihypertensive drug use, thyroid hormone and cor-
ticoid use and ACE inhibitors use) were compared between genotype groups 
using the chi-squared test. Continuous variables, which were not normally 
distributed, (age at entry and BMI) were compared using the independent 
sample Mann-Whitney test. First, we performed a logistic regression analysis 
to assess the risk of breast cancer according to the AGT M235T and AGTR1 
C573T polymorphisms, including incident and prevalent patients. For these 
analyses we implemented a regression model, which included all our proposed 
covariates. Additionally, we tested for the interaction between AGT genotype 
with HRT and BMI since these risk factors have been associated with an in-
creased AGT mRNA expression and increased AGT plasma levels (28-31). As 
a second step, we studied only incident or newly diagnosed patients to deter-
mine a breast cancer free survival by AGT and AGTR1 genotype separately. 
For this analysis, a Cox proportional hazards model was fitted using age as the 
underlying time of the model. Interaction between genes was tested using a 
multiplicative model. Furthermore, we tested for interactions between these 
two genes and ACE. We used SPSS v 11 for the logistic regression analysis and 
S-plus v 6 for the survival analysis and the plots.
Results
At baseline, 62 women had been previously diagnosed with postmenopausal 
breast cancer. During the 13 years of follow-up, another 161 women were di-
agnosed of breast cancer. The allele frequencies of both polymorphisms were 
in Hardy-Weinberg equilibrium proportions (p = 0.5 for AGT and p=0.09 
for AGTR1) in the analyzed populations. Table 1 shows that breast cancer pa-
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tients were significantly older (age at entry) (p=0.009), died significantly ear-
lier (age at death) (p< 0.0001) and had a higher BMI than controls (p=0.035). 
As we are studying genes involved in hypertension, patients and controls were 
compared for hypertension related factors. There were no significant differ-
ences in the different risk factors between cases and controls.
Figures 1 and 2 show the number of prevalent and incident breast cancer 
cases for the AGT (Figure 1) and AGTR1 (Figure 2) genes. When taking 
into account all cases, women carrying the MM genotype of the M235T 
Table 1.- Characteristics of the study population
Cases Controls Overall
Number of participants 203(3.8) 3323(96.2) 3526
Mean Age of Entry (SD) 67.6(7.8) 69.8(9.3) 69.7(9.2)*
Mean Age at Death 77.1(8.6) 83.6(8.7) 83.2(8.8)*
Mean Age at Menopause (SD) 49.47(5) 48.82(5.3) 48.85(5.3)
Mean Number Of Children (S.D) 1.9(1.5) 2.1(1.7) 2.11(1.7)
Parity (%) (≥ 1 child) 156(78.4 2561(80) 2717(79.9)
HRT (%) 24(17) 535(16.3) 559(16.3)
Hypertension (%) 55(38.2) 1253(37.1) 1308(37.1)
Use of Anti-Hypertensives(%) 14(9.7) 430(12.7) 444(12.6)
Mean Body Mass Index (SD) 27.4(3.9) 26.7(4.1) 26.8(4.1)*
* = p-value < 0.05
Figure 1. Distribution of Breast Cancer by AGT Genotype
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AGT polymorphism at baseline were more likely to have breast cancer in 
comparison to the other two genotype groups (p= 0.03). The same effect is 
seen in incident cases (p=0.02). For the AGTR1 polymorphism, there was a 
slight excess of TT carriers among patients, but no significant difference was 
seen among genotypes, neither in overall or incident cases.
To study the effect of other risk factors for breast cancer, we performed a 
logistic regression analysis entering our covariates using the forward method. 
This procedure left age at entry, HRT and BMI in the model as significant 
risk predictors. The odds ratio (OR) for MM carriers adjusted for age at entry, 
HRT and BMI was 1.4 (95% CI: 1.1-1.9, p = 0.02) when studying both 
prevalent and incident cases. When studying only the incident cases, the lo-
gistic regression analysis yielded an adjusted OR of 1.6 (95% CI: 1.1-2.1, p = 
0.01) for MM carriers versus the MT and TT carrier group. Further adjust-
ment of this model for antihypertensive drug use, smoking and parity did 
not modify these findings. There was no significant increase in breast cancer 
prevalence at baseline for MM carriers.
We tested for a possible interaction between the AGT gene and other risk 
factors that influence AGT plasma levels. When studying the interaction be-
tween the AGT gene and HRT we found that among carriers of the MM 
genotype, those using HRT had an OR of 2.2 (95% CI= 0.9-5.8) for overall 
cases and an OR of 1.9 (95% CI= 0.6-5.6) for incident cases, when compared 
to non-users. Furthermore, there was no significant interaction between BMI 
and AGT (p for interaction = 0.36).
Next we performed a Cox regression analysis, using incident cases only, 
to calculate the age specific risk for MM carriers of the AGT M235T poly-
Figure 2. Distribution of Breast Cancer by AGTR1 Genotype
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morphism. The analysis was adjusted for HRT and BMI. This model yielded 
a hazard ratio for breast cancer of 1.5 (95% CI: 1.1-2.2, p-value = 0.002) for 
MM carriers versus non-carriers (figure 3).
When studying the effect of the AGTR1 polymorphism on breast cancer 
risk using logistic regression, we found a non-significant difference in risk 
for CC carriers against TT carriers in overall (OR= 0.9, 95% CI= 0.7 -1.3), 
incident (OR= 1.0, 95% CI= 0.7 – 1.4) and prevalent cases (OR= 0.8, 95% 
CI= 0.5 -1.5). These odd ratios were adjusted for age at entry, HRT, BMI and 
age at last menstrual period. The disease free survival by AGTR1 genotype 
showed that the CC and CT carriers combined showed a lower risk for breast 
cancer, but the risk was not statistically increased compared to the TT geno-
type (figure 4).
Finally, we did not find any interaction between these two genes and the 
ACE I/D polymorphism (P interaction AGTxACE =0.86, P interaction AGTR1xACE 
= 0.44, P interaction AGTXAGTR1 =0.9).
Figure 3.- Breast Cancer Free Survival by AGT M235T Genotype
 
Figure 3.- Breast Cancer Free Survival by AGT M235T Genotype 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.- Breast Cancer Free Survival by AGTR1 Genotype 
 
 
 
 
 
 
 
 
 
Chapter 5 
 
   
 
 
 
 
 
  
Differential roles of Angiotensinogen and Angiotensin Receptor type 1 Polymorphisms
41
Discussion
We found that postmenopausal women who were homozygous for the M 
allele of the M235T AGT polymorphism had a significantly increased risk 
for breast cancer. This was seen particularly in incident cases. This effect was 
maintained at all ages independently of well-known risk factors. On the other 
hand we found no association between AGTR1 C573T genotype and risk for 
breast cancer.
Our study is the first one to assess the relationship between the M235T 
polymorphism in the AGT gene and the C573T variant in the AGTR1 gene 
and the susceptibility to breast cancer. Our aim was to unravel the relationship 
between these two polymorphisms and breast cancer risk in postmenopausal 
women. An increase in AGT could hypothetically lead to an increase in ATII, 
which is a potent growth factor, this might not be necessarily the case, since 
unlike ATII, AGT has antiangiogenic actions and reduces endothelial cell 
proliferation and migration (6). Our findings suggest that the antiprolifera-
tive actions of AGT may override the proliferative effects of angiotensin II, 
since women who carry the allele associated with low levels of AGT are at an 
increased risk for breast cancer.
Figure 4.- Breast Cancer Free Survival by AGTR1 Genotype
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Although the M235T polymorphism is not the functional one (32), it is 
in linkage disequilibrium (D’=0.94-1) with two functional variants located 
in the promoter region of the AGT gene. These two variants, the G-6A (17, 
32-35) and the C-20A (17, 33, 36) are situated within an estrogen responsive 
element (17, 29, 35). It has been well documented that estrogen increases 
AGT mRNA expression (28) and this could be assumed by our results of the 
interaction of AGT genotype and the use of HRT.
The functionality of the different variants of the AGTR1 gene has not yet 
been unraveled. The +1166A/C polymorphism located in the 3’ UTR (19) is 
in complete LD with the C573T (19), and has been consistently associated 
with hypertension, cardiovascular disease and responsiveness to AGTR1 re-
ceptor blocking agents. Moreover, the C allele of the C573T variant has been 
found to be significantly more frequent in cases on myocardial infarction (19) 
and microalbuminuria in hypertensive patients (20), although results have 
been inconsistent for the latter (37-39).
There is only one other study assessing the risk of breast cancer by AGTR1 
polymorphisms. Koh et al performed this study in Chinese women in Singa-
pore, including three different polymorphisms (40). He found that carriers 
of putative risk alleles of polymorphisms in the AGTR1 gene had a non-
significantly decreased risk of breast cancer. Our results show the same trend 
as Koh et al, although the studied polymorphisms were different. These results 
ask for further studies on this polymorphism in larger case series.
Our findings suggest that the M235T polymorphism in the AGT gene 
may play a role as susceptibility factors in breast cancer development and 
disease free survival in Caucasian postmenopausal women. This finding is in 
line with the association we have found between the ACE gene and breast 
cancer (9). The role of AGTR1 C573T polymorphism on the other hand, 
remains to be further studied.
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Abstract
Interleukin-6 (IL-6) is a growth factor involved in many processes includ-
ing carcinogenesis. The C allele of the G–174 C promoter single nucleotide 
polymorphism (SNP) in the IL-6 gene decreases levels of IL-6 expression and 
it has been studied in the context of breast cancer progression yielding con-
tradicting results. Furthermore a recent study found that carriers of the C 
allele were at an increased risk for this disease. We aim to evaluate the associa-
tion between this variant and breast cancer risk in Caucasian postmenopausal 
women. Women participating in the Rotterdam Study (N=3822), including 
171 patients with breast cancer were genotyped for this polymorphism. In 
order to assess the relationship between this SNP and breast cancer we car-
ried out a logistic regression in relation to the incidence of breast cancer. The 
C allele frequency was 41.3% and the genotypes followed Hardy-Weinberg 
distribution (p=0.3). The logistic regression analysis showed a slight increase 
of risk for C allele carriers (odds ratio= 1.24, 95% CI: 0.8-1.9), compared to 
non-carriers of this allele. This increased risk was not statistically significant. 
Our data suggest that the IL-6 –G-174 C polymorphism does not seem to 
play a role in breast cancer risk, although its role as a prognostic factor re-
mains to be studied.
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Introduction
Breast cancer is the most common malignancy in the western world. One of 
the most important and consistent risk indicators is family history (1), showing 
that genetic factors play an important role in its etiology. These genetic factors 
have not been defined thoroughly, however, analysis of functional variants in 
candidate genes offers a plausible approach to identify them. Interleukin-6 
(IL-6) is a pleiotropic growth factor that is involved in inflammation and 
carcinogenesis (2-5), acting as a regulator in many malignant tumors (6), and 
high serum levels of IL-6 have been consistently associated with advanced 
staging and poor prognosis for a variety of cancers including ovarian, breast 
and colon in some publications (2, 4, 7-9); while in others, high levels of IL-6 
and mRNA expression within breast cancer tissue have been associated with 
better prognosis and a less aggressive phenotype. The latter would suggest an 
inverse relationship between tumor aggressiveness and this cytokine (4, 10-
12). If IL-6 levels affect prognosis, one may argue that it might also influence 
the risk of disease through a similar pathway.
The IL-6 gene is located in chromosome 1q21.3 and a well known poly-
morphism located in the promoter region at position –174 has been associated 
with levels of circulating IL-6, where a G>C substitution decreases protein 
expression by reducing promoter activity (7, 13, 14).
Several studies have been performed to assess the relationship between the 
G-174 C polymorphism and breast cancer prognosis (1, 4, 5), while only one 
study has studied this variant in association to breast cancer risk and reported 
a relationship between the C allele and an increased risk for breast cancer 
(15).
In this study we evaluate the association between the –174 G>C poly-
morphism and breast cancer risk in a population-based series of Caucasian 
postmenopausal women.
Patients and Methods
Study Population
Our study population is part of the Rotterdam study, a population-based 
follow-up study of determinants of diseases in the elderly. All inhabitants of 
Ommoord, a suburb of Rotterdam, aged 55 years or older were invited to 
participate. The study design has been previously described (16). Informed 
consent was obtained from all participants and the Medical Ethics committee 
of the Erasmus Medical Center approved the study. Out of 7.983 participants 
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(response rate of 78%) examined at baseline (1990 to 1993), 4878 (61%) 
were women.
Measurements
At baseline, information on age, smoking behavior, parity and number of 
children, hormone replacement therapy (HRT), age at menopause and medi-
cal history was obtained by an interview (16). Body mass Index (BMI) was 
calculated by dividing the weight in kilograms by the height (in meters) 
squared (17).
Cancer Diagnosis
Histologically confirmed breast cancer diagnoses and incidence dates were 
obtained from the discharge registries of Rotterdam hospitals, the Daniel 
den Hoed cancer clinic and PALGA (18) a Dutch nation-wide registry of 
histo- and cytopathology. All diagnoses until February 2003, both in situ and 
invasive carcinomas, were included in the analyses. In total, 61 prevalent and 
110 incident patients were ascertained.
Genotyping
The IL-6 G–174 C polymorphism was genotyped in 3822 (78.4%) of the 
women participating in the Rotterdam Study. It was performed in whole blood 
using samples stored at –80 ° C. DNA was extracted with proteinase K and 
sodium dodecyl sulfate digestion at 37°C overnight and purified with phenol-
chloroform extractions. The extracted DNA was then precipitated with NaCl 
at 4 mol/L and 2 volumes of cold absolute ethanol. DNA was solubilized in 
double-distilled water and stored at -20°C until used for DNA amplification. 
Genotypes were determined in 5-ng genomic DNA with the Taqman allelic 
discrimination assay (Applied Biosystems, Foster City, California). Primer and 
probe sequences were optimized by using the SNP assay-by-design service of 
Applied Biosystems (for details, see http://store.appliedbiosystems.com). Re-
actions were performed with the Taqman Prism 7900HT 384 wells format.
Data Analysis
Markov-Chain Monte-Carlo approximation of the exact test from the GE-
NEPOP package V 3.3 (19) was used to test Hardy-Weinberg equilibrium 
(HWE) of the G–174 C polymorphism. Categorical variables (such as parity 
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and number or children, HRT) were compared between genotype groups 
using the chi-squared test. Continuous variables, which were not normally 
distributed, (age at entry, age at menopause and BMI) were compared using 
the independent sample Mann-Whitney test. We performed a logistic regres-
sion analysis using all our breast cancer cases to obtain the maximum power 
possible. We adjusted for possible confounders such as age at entry, age at 
menopause and BMI. These variables were selected from well-known breast 
cancer risk factors (20), such as hormone replacement therapy, parity and 
number of children, age at menarche using the forward method. The analysis 
was performed using SPSS for windows software package version 11.0.
Results
There were a total of 4878 postmenopausal women included in the Rotter-
dam study; out of whom 3905 (80%) gave DNA samples. From this number, 
3822 (78.4%) were successfully genotyped. The frequencies of the G–174 C 
genotypes of the IL-6 gene were in Hardy-Weinberg equilibrium proportions 
(p = 0.3). In table 1 we show the descriptive statistics of the study population, 
cases were found to be younger at entry, had a younger age at death and had 
fewer children than controls. Furthermore, we evaluated the distribution of 
the studied variables among genotypes and there were no significant differ-
ences between them (data not shown).
At baseline, 61 postmenopausal women entered the study with previously 
diagnosed breast cancer and 110 were diagnosed during follow up. There was 
no significant difference in the distribution of genotypes when comparing 
Table 1. General Characteristics of the study population stratified by IL-6 G–174 C 
genotype
Cases Controls Overall
Number of Participants (%) 171(4.7) 3651(95.3) 3822
Mean Age of Entry (SD) 67.8(7.6) 70.8(9.6) 70.2(9.5)*
Mean Age at Death 77.1(8.5) 84.4(8.6) 84.1(8.7)*
Mean Age at Menopause (SD) 48.8(5.1) 49.4(4.7) 48.8(5.1)
Mean Number Of Children (SD) 1.8(1.6) 2.1(1.7) 2.1(1.7)*
Parity (%) (≥ 1 child) 125(73) 2661(73) 2786(73)
HRT (%) 30(17) 509(14) 539(15)
Mean Body Mass Index (SD) 26.7(4.1) 27.1(3.9) 26.7(4.1)
* = p-value < 0.05
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all, incident or prevalent to controls. Table 2 shows the genotype frequencies 
in the cohort and breast cancer cases as well as the odds ratios. The logistic 
regression analysis, adjusting for age at entry, age at menopause and BMI 
yielded an odds ratio (OR) of 1.24 (95% CI= 0.8-1.9, p-value = 0.3) for C 
allele carriers vs. non carriers, when taking into account all the cases, 1.12 
(95% CI= 0.7-1.7, p-value = 0.6) for incident cases and 1.23 (95% CI= 0.7-
2.2, p-value= 0.5) for prevalent cases.
Discussion
In order to study the relationship between the IL-6 G–174 C polymorphism 
and breast cancer we performed a logistic regression in a population based co-
hort study. We found no statistically significant association between genotype 
and the risk of breast cancer, except for a slightly increased risk for the C allele 
carriers, the allele that has been linked to lower levels of IL-6 expression (7, 
13, 14). Nevertheless, our results show the same trend reported by Hefler et al 
(15) who showed an increased risk for breast cancer for C allele carriers.
Cytokines are potent stimulators of the immune system, and have been 
shown to be secreted by peritumoral lymphocytes in breast tumors (1). It 
would be therefore plausible to assume that a polymorphism predisposing to 
low IL-6 levels could increase the risk of cancer by decreasing immunological 
response to this disease (5). Still, it is interesting that elevated serum levels of 
IL-6 have been associated with more advanced disease in many types of cancer 
including colon (7), ovarian (2) and breast (9) in some studies. Moreover, 
it is unclear whether this increase in plasmatic levels of IL-6 is a cause or a 
consequence of the advance staging of the tumor (4).
Table 2. Genotype frequencies and ORs for Breast Cancer by IL-6 G–174 C Genotype.
Genotype
GG GC CC
Participants (%) 1341(35.1) 1819(47.6) 662(17.3)
Total Cases (%) 55(32.2) 86(49.7) 30(18.1)
Incident Cases (%) 36(32.7) 54(49.1) 20(17.2)
ORs GC+CC
Overall ref 1.24 (95% CI 0.8-1.9, p-value=0.3)
Incident ref 1.12 (95% CI 0.7-1.7, p-value=0.6)
Prevalent ref 1.23 (95% CI 0.7-2.2, p-value=0.5)
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We did not find evidence for a significant effect of the IL-6 gene on breast 
cancer risk. CC carriers had a consistent but small increase in risk compared 
to GG carriers. The small number of cases (n=171) could account for lack of 
power in an association analysis of such a small effect. Extremely large num-
bers of patients need to be screened in order to exclude such a small effect on 
the risk or progression of breast cancer.
Our findings suggest that the G-174 C polymorphism in the IL-6 gene 
does not seem to play a role as a risk factor for breast cancer.
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Abstract
TGF-β1 has dual role in carcinogenesis. In this gene, a leucine to proline 
substitution in codon 10 leads to higher circulating levels of TGF-β1. This 
variant has been studied in relationship to the risk for breast cancer yielding 
contradicting results. We aim to unravel the relationship of this polymor-
phism and the risk of breast cancer. Women participating in the Rotterdam 
Study including 143 patients with incident breast cancer were genotyped for 
this polymorphism. We carried out a logistic regression and a survival analy-
sis using age as the time variable. The logistic regression analysis showed an 
increased risk of breast cancer for Proline carriers (OR=1.4; 95%CI =1.1-2.0) 
versus non-carriers. The survival analysis showed that carriers of the same 
allele had an increased risk of breast cancer (HR = 1.4, 95% CI = 1.1-2.0) 
against non-carriers.
Our data suggests that the TGF-β1 Leu10Pro polymorphism might play a 
role in breast cancer risk.
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Introduction
The proliferation of cancerous breast epithelial cells is regulated by different 
stimuli including cytokines and growth factors (1), such as the transforming 
growth factor β (TGF-β). TGF-β has three isoforms TGF-β1, TGF-β2 and 
TGF-β3. TGF-β1 is the most abundant and universally expressed isoform (2). 
It is known to be expressed in endothelial tissue (3) and has an effect on 
the growth of mammary epithelium (4). Furthermore, it has recently been 
suggested that TGF-β1 has a dual role in tumor growth. It acts as a tumor 
suppressor inhibiting epithelial cell proliferation in early stages and as a tumor 
promoter in later stages of carcinogenesis (5). Both activities of TGF-β have 
been clearly demonstrated in genetically modified mouse lines in which the 
TGF-β signaling pathway is ablated or modified (6). These studies imply that 
TGF-β isoforms inhibit the development of early, benign lesions but enhance 
invasion and metastasis when the tumor suppressor activity is overridden by 
oncogenic mutations in other pathways (7).
The gene encoding for TGF-β1 is located on chromosome 19q13.1. A 
T29C transition that results in a Leu10Pro substitution in the signal peptide 
sequence in this gene has been associated with higher circulating levels of 
TGF-β1. Proline homozygotes have been found to have increased serum levels 
of TGF-β1 (8, 9). This variant has been studied in relationship to the risk for 
breast cancer but these studies have been inconclusive (10-17). The aim of 
this study is to examine the relationship of the Leu10Pro polymorphism and 
the risk of breast cancer in an association study.
Material and Methods
Study Population
Our study population is part of the Rotterdam study (18) where inhabit-
ants of Ommoord, a suburb in Rotterdam, aged 55 or older were invited to 
participate and 7983 agreed to do so (response rate =78.1%). Participants’ 
informed consent was obtained and the Medical Ethics Committee of the 
Erasmus Medical Center approved the study. Our study group was comprised 
of 4878 postmenopausal women.
Measurements
Information on risk factors such as age at menarche, age at menopause, hor-
mone replacement therapy use (HRT) was retrieved at baseline. Body Mass 
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Index (BMI) was calculated by dividing the weight in kilograms by the height 
(in meters) squared.
Case Identification and Validation
Three different databases were used for case identification. First, cases diag-
nosed by general practitioners in the research area (Ommoord) were collected 
(International Classification of Primary Care (X76)). Second, the Dutch 
National Registry of all hospital admissions (LMR) was consulted to detect 
all malignancy related hospital admissions for study participants. Finally, re-
gional pathology databases were linked to the Rotterdam Study to identify 
cases. Subsequently, breast cancer cases were validated by a physician on the 
basis of medical records of the general practitioner, discharge letters and pa-
thology reports. Only pathologically confirmed cases were considered in the 
analysis. The index date was defined as the earliest date found in the pathol-
ogy report.
Genotyping
Of the 4878 women participating in our study, there were 3905 DNA samples 
available for genotyping. Of these, 3646 (93.4%) were successfully genotyped. 
The genotyping procedures have been previously described (21).
Data Analysis
We tested Hardy-Weinberg equilibrium (HWE) of the TGF-β1 Leu10Pro 
polymorphism using Markov-Chain Monte-Carlo approximation of the 
exact test implemented in the GENEPOP package V 3.3 (22). Categorical 
variables, such as parity and hormone replacement therapy (HRT), were com-
pared between genotype groups using the chi-squared test. Continuous vari-
ables, (age at entry, age at menopause, BMI and waist hip ratio (WHR) were 
compared between genotypes using the independent sample Mann-Whitney 
test. We used logistic regression to study the risk of breast cancer by TGF-β1 
genotype. We adjusted for possible confounders such as age at entry, age at 
menopause, HRT, WHR and BMI. Then, we performed a Cox proportional 
hazards model to assess breast cancer free survival by TGF-β1 genotype. The 
logistic regression was performed in SPSS version 11 and the disease free sur-
vival was done in S-plus version 6.
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Results
The frequencies of the Leu10Pro genotypes of the TGF β1 gene were in Hardy-
Weinberg equilibrium proportions (p= 0.98). The descriptive statistics of our 
study population are shown in table 1. The distribution of these risk factors 
was not significantly different among genotype groups.
At baseline there were 66 prevalent postmenopausal breast cancer cases 
while another 143 were diagnosed during follow-up. The prevalent cases were 
not included in our analyses. We did not find any statistically significant dif-
ferences between the distribution on risk factors in women who were and 
women who were not successfully genotyped (data not shown).
Table 1.- General Characteristics of the study population stratified by TGF-β1 genotype
Genotype Leu/Leu Leu/Pro Pro/Pro Total
Total Studied (%) 1488(40.8) 1679(46.1) 479(13.2) 3646
Mean Age of Entry (SD) 70.2(9.5) 70.4(9.5) 69.6(9.4) 70.2(9.5)
Mean Age at Death 84.3(8.8) 83.5(8.9) 83.9(8.6) 83.9(8.8)
Mean Age at Menopause (SD) 52(13.5) 51.7(12.6) 51.5(18.1) 51.8(12.8)
Mean Number Of Children 2.1(1.7) 2.1(1.7) 2.2(1.8) 2.1(1.7)
Parity (%) (≥ 1 child) 1135(79.3) 1278(79) 373(81) 2786(79.4)
HRT (%) 272(19.7) 248(19.3) 63(18.4) 533(19.4)
Mean Body Mass Index (SD) 26.81(4.1) 26.71(4.1) 26.47(3.8) 26.72(4)
Mean Waist-Hip Ratio (SD) 0.87(0.1) 0.87(0.1) 0.86(0.1) 0.88(0.1)
Figure 1.- Breast cancer cases by Genotype
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Figure 2.- Disease Free Survival by Genotype 
 
P= chi-square p-value
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The distribution of breast cancer in our population stratified by the TGF 
β1 genotype is shown in Figure 1. The figure shows that the incidence of 
breast cancer in carriers of at least one proline allele was statistically higher 
(p= 0.04) than non-carriers. Since the distribution for homozygotes carriers 
of proline was similar to that of heterozygotes, we pooled heterozygous and 
homozygous carriers in the logistic regression model, which we used to adjust 
for known risk factors. The odds ratio was 1.4 (95% CI = 1.1-2.0, p= 0.04). 
According to our power calculations our number of cases was sufficient to 
find an effect of this size.
Additionally, we performed a disease free survival analysis. We found that 
carriers of the proline allele had a HR of 1.4 (95% CI = 1.2-2.0, p= 0.04) 
compared to non-carriers (Figure 2). This effect was independent of well-
known risk factors such as HRT and BMI.
Discussion
In this association study we show a statistically significant increase in risk of 
breast cancer for carriers of at least one copy of the proline allele of the Leu10-
Pro polymorphism in the TGF-β1 gene, when compared to non-carriers in 
Figure 2.- Disease Free Survival by Genotype
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Caucasian postmenopausal women. Our research is part of the Rotterdam 
Study, a population based cohort study for disease determinants in the elderly. 
The strength of our study is based on its prospective basis but although we did 
find significant evidence for an association between genotype and disease, our 
study had some limitations. The first one is that only a few number of breast 
cancer cases were diagnosed during follow up. Nevertheless, this number is 
sufficient to detect a moderately increased risk as the one we do, according to 
our power calculations. The second one is that 21% of the women entering 
the study did not give a DNA sample.
These women were older at entry, at death and at menopause and they 
were also less likely to have children or receive HRT. These women were less 
likely to develop breast cancer, and including them in our analysis could have 
driven our results towards the null.
TGF-β1 is a cytokine that has been linked to both tumor inhibition (3, 23) 
and promotion (5) at different stages of carcinogenesis in the breast tissue. A 
priori it is therefore difficult to predict the effect of the protein as well as the 
gene encoding for it. The Leu10Pro polymorphism has been related to higher 
serum levels of TGF-β1 (9). It has been hypothesized that polymorphisms 
that affect the level of expression of this cytokine may alter an individual’s 
susceptibility to cancers including breast (24). We found that women with the 
allele associated with higher levels of TGF-β1 have an increased risk for breast 
cancer. According to these findings, the tumor suppressor properties of TGF-
β1 would be rapidly exceeded by breast epithelial cells prone to oncogenesis.
While the majority of studies could not elucidate a clear relationship be-
tween TGF-β1 and breast cancer risk (12-14), in 2 studies, an increased risk 
for proline allele carriers was found (1, 11). Three other studies did not find 
a difference in risk (12-14) and one found an inverse association between the 
proline allele and breast cancer (10). The latter was conducted in women over 
65 years old.
In conclusion, our results suggest that the proline allele of the Leu10Pro 
polymorphism in the TGF-β1 gene may play a role in the predisposition to 
breast cancer in Caucasian postmenopausal women.
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Abstract
IGF-I is an important growth factor for the mammary gland. We evaluated 
the relationship of the IGF-I CAn polymorphism with breast cancer risk in 
Caucasian postmenopausal women and perform a meta-analysis of published 
data. The IGF-I CAn polymorphism was genotyped in 4091 from the Rot-
terdam Study. A disease-free survival analysis was performed along with a 
meta-analysis of all available data on IGF-I CAn polymorphism and breast 
cancer risk. During follow-up 159 women were diagnosed with breast cancer. 
The disease-free survival analysis adjusted for age at entry, age at menopause, 
body mass index and waist hip ratio yielded a HR= 0.97 (95% CI=0.59-1.58) 
for CA19 non-carriers against carriers. The meta-analysis using the random-
effects model gave a pooled OR of 1.26 (95% CI=0.95-1.82) for IGF-I CA19 
non-carriers versus CA19 homozygous carriers.
According to these results the IGF-I CA19 promoter polymorphism is not 
likely to predict the risk of breast cancer.
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Introduction
Insulin-like growth factor I (IGF-I) is a paracrine and autocrine growth factor 
that is secreted by many tissues (1, 2). In animals and humans its expression 
along with its receptor is necessary for normal growth and development (1). 
IGF-I has also been implicated in tumor growth and metastasis (1). Various 
studies have associated elevated serum levels of IGF-I with an increased risk 
for colorectal, prostate and pre menopausal breast cancer (3-5).
In the breast, stromal cells of the mammary connective tissue as well as 
adipocytes produce IGF-I since it is important in their differentiation (6). 
Furthermore, IGF-I plays an important role in the proliferation and survival 
of the mammary gland cells particularly during puberty and pregnancy when 
proliferation occurs (7). IGF-I is also a potent mitogen and through this path-
way the genes encoding for such proteins may be involved in cell prolifera-
tion.
Twin studies have determined that about 50% of the variability of circulat-
ing levels IGF-I is genetically determined (8). The IGF-I gene is located on 
chromosome 12q22-q24.1 where a cytosine adenine (CA) repeat in the gene’s 
promoter region has been associated with plasma IGF-I levels (9, 10). The 
CAn repeat polymorphism is located 1 kb upstream from the transcription 
start site and in our study population, homozygote carriers of 19 (CA19) re-
peat allele have been associated with lower plasma IGF-I levels (10), while in 
another study the opposite was found (9). A few studies have assessed the risk 
of breast cancer according to carriership of the CA19 allele of this polymor-
phism (11-17) generating contradicting results. These include a meta-analysis 
(13) of four studies that yielded a statistically significant increased risk for car-
riers of the CA19 allele, nevertheless there have been new publications on this 
association. Since the association between this variant and breast cancer is still 
not clear, especially in postmenopausal women, a nested case-control study 
was performed along with a meta-analysis of published data on the risk for 
this disease and this polymorphism, so as to clarify the relationship between 
this variant and the risk of breast cancer.
Patients and Methods
Study Population
Our study population is part of the Rotterdam study (18), a follow-up study 
established between 1990 and 1993. Inhabitants of a suburb of Rotterdam 
aged 55 or older were invited to enroll and 7983 agreed (response rate = 
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78.1%). All subjects signed an informed consent approved by the Medical 
Ethics Committee of the Erasmus Medical Center.
Measurements
Information on well-known risk factors for breast cancer such as age at me-
narche, age at menopause, body mass index (BMI), hormone replacement 
therapy (HRT), waist hip ratio (WHR), parity and number of children, were 
retrieved at baseline through a questionnaire, the methodology of this study 
has been described previously (18). BMI was calculated by dividing the weight 
in kilograms by the height (in meters) squared.
Cancer Diagnosis
Three different databases were used for case identification. First, cases diag-
nosed by general practitioners in the research area (Ommoord) were collected. 
Second, the Dutch National Registry of all hospital admissions (LMR) was 
consulted to detect all malignancy related hospital admissions for study par-
ticipants. Finally, regional pathology databases were linked to the Rotterdam 
Study to identify cases. Subsequently, breast cancer cases were validated by a 
physician on the basis of medical records of the general practitioner, discharge 
letters and pathology reports (CS). Only identified cases that had also been 
pathologically confirmed were considered valid and were consequently used 
in the analysis. The index date (date of diagnosis) was defined as the earliest 
date found in the pathology report.
Genotyping
Of the 4878 women participating in our study, 4686 (96%) donated DNA 
samples and out of these, 4091 (87.3%) were successfully genotyped for the 
IGF-I CAn repeat. The genotyping procedures have been described earlier 
(19). Because the CA19 allele was the most common allele in our population, 
we followed the grouping procedures performed by previous authors and 
joined all other alleles to be CA-19 (13, 15). Therefore, we had three genotype 
categories, CA19 homozygotes, CA19 heterozygotes and CA19 non-carriers.
Data Analysis
We tested Hardy-Weinberg equilibrium (HWE) of the CAn repeat polymor-
phism using Markov-Chain Monte-Carlo approximation of the exact test 
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implemented in the GENEPOP package V 3.3 (20). Since this is a follow-up 
study, we evaluated if loss to follow-up was dependent of genotype or other 
risk factors for breast cancer. Categorical variables such as parity, hormone 
replacement therapy (HRT), were compared between genotype groups using 
the chi-squared test. Continuous variables, (age at entry, age at menopause, 
BMI and WHR were compared using the independent sample Mann-Whit-
ney test. In order to calculate disease-free survival, a Cox proportional hazards 
model was fitted using age as the underlying time of the model and taking 
the CA19 homozygotes as the reference category since these have been associ-
ated with low levels of circulating IGF in our population (10). Only incident 
cases were used in this analysis due to the fact that age at entry was used as 
the underlying time of the Cox proportional hazards model. We adjusted for 
possible confounders such as age at entry, age at menopause, WHR and BMI 
since this variables could be dependent of genotype.
Meta-Analysis
We searched PubMed until February 2007 for all case-control studies on the 
association of the IGF-I CAn repeat variant and breast cancer. Our search 
strategy was based on the key word “breast cancer” combined with “IGF” 
and “polymorphism”. To verify that all studies were retrieved, the reference 
lists of all publications were searched for additional studies. Articles were not 
included if genotype frequencies were not complete. In this analysis no time 
dependent variable was used, instead we calculated odds ratios (OR) and 95% 
confidence intervals (CI) using the random-effects model of the DerSimonian 
and Laird method (21). The degree of heterogeneity between the study results 
was tested by the inconsistency statistic (I2). Funnel plots were used to evalu-
ate publication bias (22). Data were analyzed using Review Manager, version 
4.2 (Cochrane Collaboration, Oxford, UK).
Results
The distribution of the IGF-I CAn genotypes was in Hardy-Weinberg equilib-
rium proportions (CA19 homozygous carriers = 43.8%, CA19 heterozygotes = 
44.1% and CA19 non-carriers = 12.1%, p-value=0.24). Furthermore, a total 
of 7.9% of the women participating in our study were lost to follow-up. Nev-
ertheless, this loss to follow up was independent of IGF-I genotype or risk 
factors for breast cancer. The distribution of the risk factors included in our 
study did not differ significantly between genotypes (Table 1). There were 
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67 women with previously diagnosed breast cancer and additionally, during 
follow-up, 159 were further diagnosed. Out of the 159 incident cases, we 
found that 70 cases were CA19 homozygote carriers, 53 were CA19 heterozy-
Table 1. General Characteristics of the study population stratified by IGF-I CA19 repeat 
genotype
Genotype Homozygote
carriers
Heterozygote
carriers
Non-carriers Overall
Total Studied % (N) 43.8 (1830) 35.2 (1473) 21 (878) 4181
Mean Age of Entry (SD) 70.6(9.8) 70.5(9.8) 71 (10.1) 70.7(17.5)
Mean Age at Death 84.8(8.8) 84.2(8.7) 84.1(8.6) 84.3(8.7)
Mean Age at Menopause (SD) 48.9(5.3) 48.7(5.1) 48.9(5.1) 48.8(5.1)
Mean Number of Children 2.1(1.7) 2.1(1.78) 2.0(1.6) 2.1(1.7)
Parity (%) (≥ 1 child) 79.8 (1362) 79.3 (1368) 78.7 (369) 79.4 (3099)
Hormone Replacement Therapy (%) 18.7 (247) 20.1 (275) 19.3 (73) 19.4 (595)
Waist-Hip Ratio 0.87(.09) 0.87(.09) 0.87(.09) 0.87(0.1)
Mean Body Mass Index (SD) 26.8(4.1) 26.7(3.9) 26.8(4.1) 26.7(4.1)
CA19 = CA19 allele carrier
Figure 1.- Breast Cancer Free Survival by IGF-I Genotype
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gotes and 36 were the CA19 non-carriers. There were no statistically significant 
differences in breast cancer frequency by genotype (p-value=0.82).
A disease-free survival analysis taking age at entry as the underlying time 
of the Cox proportional hazard’s model and adjusting for age at menopause, 
BMI, and WHR yielded a HR = 0.85 (95%CI= 0.52-1.39) for CA19 heterozy-
gotes versus CA19 homozygote carriers and a HR = 0.95 (95%CI= 0.56-1.62) 
for CA19 non-carriers against CA19 homozygote carriers (Figure 1). When 
pooling heterozygotes and homozygous for the CA19 repeat and compared 
them vs. the non-carriers, we obtained an HR of 0.97 (95% CI= 0.59-1.58) 
for non-carriers versus CA19 carriers. None of the covariates included in our 
analyses significantly increased the risk for breast cancer in our model.
The search for articles on the relation between the IGF-I CAn polymor-
phism and breast cancer risk retrieved eight studies. One study (13) had al-
ready carried out a meta-analysis but only included four publications in total, 
so we updated the analysis by including new available published data. Three 
studies were not included because genotyping frequencies were not complete 
(12, 17, 23). For this analysis the prevalent cases in our study population were 
Figure 2. Meta-Analysis
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included along with the incident cases. The meta-analysis yielded a pooled 
OR=1.05 (95% CI=0.95-1.17) for CA19 heterozygous carriers versus CA19 
homozygous carriers, and OR=1.26 (95% CI=0.87-1.82) for CA19 non-
carriers versus CA19 homozygous carriers, in contrast to the results found in 
our study (Figure 2). Nevertheless, there was significantly high inter-study 
heterogeneity in the meta-analysis (p-value < 0.00001 for the comparison 
between CA19 non-carriers against CA19 homozygote carriers), which makes 
the interpretation of the results difficult. The evaluation of the funnel plots 
did not show evidence of publication bias.
Discussion
We conducted a disease-free survival analysis to evaluate the role of the IGF-I 
CAn polymorphism on the risk of postmenopausal breast cancer. Additionally, 
we performed a meta-analysis using available published data. We did not find 
any difference in risk of breast cancer between the different CAn genotypes in 
our study population and the meta-analysis.
The results of our study yielded a non-statistically significant decreased 
risk for CA19 carriers while the meta-analysis yielded a result in the opposite 
direction. However, both estimates are not significant, suggesting that this 
polymorphism is not associated with breast cancer risk. Nevertheless, findings 
in the meta-analyses including 3574 patients were also negative.
Polymorphisms that influence the level of expression of IGF-I are likely 
to affect lifetime exposure to this molecule by both endocrine and autocrine 
mechanisms (24). The evaluation of the IGF-I promoter variant presented here 
allows us to evaluate lifetime exposure to circulating levels of IGF-I decrease 
substantially with age (25). Earlier, we have shown that this polymorphism 
is associated with plasma levels of IGF-I (10). Our findings are in according 
to those of patients with postmenopausal breast cancer showing not effect of 
IGF-I plasma serum levels (24). Moreover, there is some evidence for an effect 
of serum IGF-I in premenopausal breast cancer, which may be explained by 
interaction of IGF-I with estrogen (26).
It should also be taken into account that the small number of cases (n=159 
incident) in the performed analysis, could account for lack of power in an 
association analysis of such a small effect as is expected from common variants 
(27). Our findings suggest that genetically determined IGF-I exposure is not 
relevant for post-menopausal breast cancer.
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Abstract
The estrogen receptor alpha (ESR1) is a mediator of estrogen response in the 
breast. The most studied variants in this gene are the PvuII and XbaI polymor-
phisms, which have been associated to lower sensitivity to estrogen. We evalu-
ated whether these polymorphisms were associated with breast cancer risk by 
means of an association study in a population of Caucasian postmenopausal 
women from the Rotterdam study and a meta-analysis of published data. 
The PvuII and XbaI polymorphisms were genotyped in 3893 women partici-
pants of the Rotterdam Study. Baseline information was obtained through a 
questionnaire. We conducted logistic regression analyses to assess the risk of 
breast cancer by each of the ESR1 genotypes. Meta-analyses of all publica-
tions on these relations were done by retrieving literature from Pubmed and 
by further checking the reference lists of the articles obtained. There were 38 
women with previously diagnosed breast cancer. During follow-up, 152 were 
additionally diagnosed. The logistic regression analyses showed no difference 
in risk for postmenopausal breast cancer in carriers of the PvuII or XbaI geno-
types neither in overall, incident or prevalent cases. No further evidence of a 
role of these variants was found in the meta-analysis. Our results suggest that 
the ESR1 polymorphisms do not play a role in breast cancer risk in Caucasian 
postmenopausal women.
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Introduction
Family history is one of the strongest risk factors for breast cancer (1). It has 
been shown that the heritability of this disease is ~30% (2). The most impor-
tant determinants of risk for breast cancer are related to endogenous hormone 
levels and major reproductive events (3), thus, suggesting that genes in the 
estrogen pathway may influence breast cancer risk.
The estrogen receptor alpha (ESR1) is one of the most important media-
tors of hormonal response in estrogen-sensitive tissues such as the breast (4) 
and plays a crucial role in breast growth and differentiation as well as in the 
development of cancer (5). The human ESR1 gene is localized on chromo-
some 6q24-q27 (6), it extends more than 140 kb and includes eight exons (7). 
The most studied variants in this gene are the PvuII (C/T) and XbaI (G/A) 
polymorphisms in intron 1, 397 and 351 bp upstream of exon 2 respectively 
(8, 9). These variants have been implicated in gene expression by influencing 
transcription (10). While some studies have found an increased risk for the 
A and T alleles of the XbaI and PvuII polymorphisms (4, 9, 10), others have 
found an increased risk only for the X (G) allele of XbaI (11, 12). In addition, 
other studies found no effect at all for either of these polymorphisms (4, 13). 
These alleles were correlated with high bone mineral density and height in 
other studies, including one performed in our study population, (14, 15), 
suggesting a stronger estrogenic effect in P (C) and X (G) allele carriers (14).
The aim of our study was to evaluate the effect of these polymorphisms 
on breast cancer risk by performing an association analysis in a population 
based study of Caucasian postmenopausal women. Further, we performed 
meta-analyses of all available published data on these polymorphisms and the 
risk of breast cancer.
Materials and Methods
Study Population and Measurements
Our study population is part of the Rotterdam study (16). Inhabitants of the 
suburb of Ommoord aged 55 or older were invited to participate and 7983 
agreed to do so (response rate 78.1%). Study participants signed an informed 
consent and the Medical Ethics Committee of the Erasmus Medical Center 
approved the study. Our study group was composed of 4878 postmenopausal 
women. Information on risk factors such as age at entry, age at menarche, age 
at menopause, parity, body mass index (BMI), waist hip ratio (WHR) and 
hormone replacement therapy use (HRT) was retrieved at baseline through a 
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questionnaire. BMI was calculated by dividing the weight in kilograms by the 
height (in meters) squared (17).
Case Identification and Validation
Three different databases were used for case identification. First, cases diag-
nosed by general practitioners in the research area (Ommoord) were collected 
(International Classification of Primary Care (X76)). Second, the Dutch 
National Registry of all hospital admissions (LMR) was consulted to detect 
all malignancy related hospital admissions for study participants. Finally, re-
gional pathology databases were linked to the Rotterdam Study to identify 
cases. Subsequently, breast cancer cases were validated by a physician on the 
basis of medical records of the general practitioner, discharge letters and pa-
thology reports. Only pathologically confirmed cases were considered in the 
analysis. The index date was defined as the earliest date found in the pathol-
ogy report.
Genotyping & Data Analysis
Out of the 4878 women participating in our study, 3893 (80 %) were suc-
cessfully genotyped for the PvuII and XbaI polymorphisms. The genotyping 
procedures have been described previously (14). Loss to follow up was as-
sessed to verify it was independent of genotype. Categorical variables, such 
as parity and hormone replacement therapy (HRT), were compared between 
genotype groups using the chi-squared test. Continuous variables, (age at en-
try, age at menopause, BMI and waist hip ratio (WHR) were compared using 
the independent sample Mann-Whitney test. We used logistic regression to 
study the risk of breast cancer by ESR1 genotype. This analysis was performed 
using SPSS version 11, since there is no clear risk allele from the literature, we 
took the TT (PvuII) and AA (XbaI) genotypes as reference because they have 
been associated to lower sensitivity to estrogen in our population (14). We 
also performed a trend test to evaluate if the number of risk alleles carried had 
an effect on disease risk. Hardy-Weinberg equilibrium (HWE) was assessed 
for both polymorphisms using Markov-Chain Monte-Carlo approximation 
of the exact test implemented in the GENEPOP package V 3.3 (18).
Meta-Analysis
We searched PubMed until October 2006 for all case-control studies on the 
association of the PvuII and XbaI polymorphisms in the ESR1 gene and 
Estrogen Receptor 1 Polymorphisms and Postmenopausal Breast Cancer Risk
85
breast cancer. Our search strategy was based on the keyword “breast cancer” 
combined with “estrogen receptor” and “polymorphism”. To verify that all 
studies were retrieved, the reference lists of all publications were searched for 
additional studies. We excluded studies from our analyses if the genotype 
frequencies in the control population were out of Hardy-Weinberg or if their 
data had been previously used in another study. To quantify the strength of 
association, pooled odds ratios (ORs) and 95% confidence intervals (CI) 
were calculated using the random-effects model of the DerSimonian and 
Laird method (19). The degree of heterogeneity between the study results was 
tested by the inconsistency statistic (I2). Funnel plots were used to evaluate 
publication bias (20). Data were analyzed using Review Manager, version 4.2 
(Cochrane Collaboration, Oxford, UK).
Results
The total loss of follow-up for the genotyped participants was 8.4% and it 
was not dependent of ESR1 genotype (p = 0.51). The genotype frequencies 
of both polymorphisms were in Hardy-Weinberg equilibrium proportions (X2 
p=0.33 for PvuII and X2 p=0.31 for XbaI). In table 1 we show the baseline 
characteristics of our study population. We found that cases were significantly 
younger at entry than controls (p< 0.001) and also died earlier during follow-
up (p< 0.001). We also found that cases had significantly fewer children than 
controls (p=0.04). We did not find any significant differences in baseline char-
acteristics between genotypes (data not shown).
Table 1. General Characteristics of the study population
Cases Controls Total
Total Studied (%) 190(4.7%) 3457(95.3) 3629
Mean Age of Entry (SD) 67.80(7.7) 70.36(9.6)* 70.24(9.6)
Mean Age at Death (SD) 77.30(8.6) 84.46(8.7)* 84.12(8.8)
Mean Age at Menarche (SD) 13.57(1.7) 13.68(1.8) 13.67(1.8)
Mean Age at Menopause (SD) 49.51(4.8) 52.19(13.6)* 52.07(13.3)
Mean Number of Children (SD) 1.77(1.6) 2.12(1.7)* 2.10(1.7)
Parity (SD) (≥ 1 child) 121(71.6) 2640(79.4)* 2761(79)
Hormone Replacement Therapy (%) 27(21.1) 504(19.5) 531(19.6)
Mean BMI (SD) 27.10(3.9) 26.67(4.1) 26.69(4.1)
Mean WHR (SD) 0.87(.09) 0.87(.09) 0.87(.09)
* p-value < 0.05
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There were 38 women with previously diagnosed postmenopausal breast 
cancer who entered the study. During follow-up, 152 were additionally di-
agnosed. For both the PvuII and XbaI genotypes, there was no significant 
difference in the number of cases between genotypes. We carried out a logistic 
regression analysis adjusting for age at entry, age at menopause, BMI, WHR 
and HRT for both polymorphisms separately (Table 2). Since the T and A 
Table 2.- Odd Ratios for breast cancer risk for PvuII and XbaI genotypes
PvuII overall incident prevalent
TT ref ref ref
CT 0.9 (0.6-1.4) 1.0 (0.6-1.6) 0.8 (0.3-2.1)
CC 1.4 (0.8-2.2) 1.4 (0.8-2.5) 1.2 (0.4-3.3)
XbaI overall incident prevalent
AA ref ref ref
GA 1.2 (0.8-1.7) 1.3 (0.8-2.0) 0.8 (0.4-1.9)
GG 1.3 (0.7-2.2) 1.5 (0.8-2.8) 0.5 (0.2-2.4)
Figure 1. Meta-Analyses ESR1 XbaI polymorphism and breast cancer risk
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alleles of these polymorphisms have been correlated to lower estrogenic ef-
fects; we used the TT and AA genotypes as our reference categories in the 
analyses. There were no significant differences in risk for breast cancer among 
carriers of the different genotypes of the PvuII or XbaI polymorphisms in 
the ESR1 gene. There was a non-significant tendency of the C allele of PvuII 
(p-for trend = 0.22) and G allele of the XbaI (p-for trend 0.26) to be over 
represented in patients.
To evaluate our data together with those in the literature we performed 
meta-analyses. We identified nine articles studying the relation between XbaI 
and PvuII polymorphisms and the risk of breast cancer (4, 9-12, 21-24). We 
excluded from our analyses one study (11), since the data was used in another 
study (4).
Furthermore, two studies were excluded since genotype frequencies of con-
trols were out of Hardy-Weinberg equilibrium proportions (9, 10). Using the 
random effects model we did not find any difference in risk among XbaI and 
PvuII genotypes (Figures 1 and 2). High inter-study heterogeneity can render 
the interpretation of the results of a meta-analysis difficult and although we 
Figure 2- Meta Analysis ESR1 PvuII polymorphism and breast cancer risk
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found high heterogeneity in the G/A versus GG comparison there was no 
significant heterogeneity in the other three comparisons. Additionally, the 
evaluation of the funnel plots did not suggest evidence for publication bias.
Discussion
We performed an association study to evaluate the relationship of two well-
studied polymorphisms in the ESR1 gene and the risk of breast cancer in 
Caucasian postmenopausal women from the Rotterdam Study. Using logistic 
regression analysis, we found no evidence of effect, with only a non-signifi-
cant increase in breast cancer risk for AA carriers of the XbaI polymorphism 
(overall OR= 1.3, 95% CI=0.7-2.2) and for TT carriers of the PvuII variant 
(overall OR= 1.4, 95% CI=0.8-2.2). Additionally we performed meta-anal-
yses of published data to examine the effect of both polymorphisms. These 
meta-analyses also suggest there are no differences in risk among genotype 
groups of these two ESR1 variants.
The XbaI and PvuII polymorphisms are situated in intron 1 and their 
functionality has not yet been demonstrated. Moreover, it has been suggested 
their effects could be the result of high linkage disequilibrium with functional 
variants that affect sensitivity to estrogen (13).One of the limitations of our 
study is the limited number of breast cancer cases present in our popula-
tion. Nevertheless, we have sufficient power (β=0.8) to detect effects of 1.6 or 
higher. We further conducted meta-analyses off all studies conducted to date. 
Our data suggests that these two polymorphisms do not play a role in the 
susceptibility of breast cancer in elderly Caucasian women.
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8.1  Searching for new genetic determinants for breast 
cancer susceptibility and scope of the thesis
In the Netherlands, breast cancer is the most common cause of cancer in 
women and has one of the highest incidences worldwide (1, 2). The major 
determinants contributing to an increased risk for breast cancer are those 
related to hormonal exposure. These can be from either endogenous or ex-
ogenous sources, such as early age at menarche, late age at menopause, late 
pregnancy or nullliparity, overweight and obesity, or use of hormone replace-
ment therapy (HRT) (3). Other risk factors include age, alcohol intake, past 
history of breast cancer and history of breast biopsy and radiation exposure 
(4). The latter being of particular interest for genetic association of various 
genes involved in DNA repair that have been carried out to date. Findings 
on smoking have been inconsistent and have been subject to debate (5, 6). 
There are some studies suggesting that genes involved in detoxification are 
relevant such as n-acetyltransferase 2 (NAT2) and glutathione-s-transferase1 
(GSTM1). Of interest is also the finding of a recent study showing that smok-
ing increases the risk of breast cancer by 3% per pack/year when it is done 
between menarche and first childbirth (7).
While part of the familial aggregation of breast cancer may be the result 
of the clustering of risk factors, for example, obesity and reproductive factors 
such as late age at full pregnancy and HRT (4), for the large majority, this 
clustering is likely to be the result of inherited susceptibility. Cancer develops 
through a series of alterations in DNA that result in unrestrained cellular pro-
liferation. While most cancers arise sporadically, familial clustering of cancers 
occurs in certain families who carry a germline mutation in a cancer gene 
(8). This is particularly true for breast cancer, where carriers of mutations in 
eleven genes (BRCA1, BRCA2, TP53, PTEN, LKB1, ATM, NBS1, RAD51, 
BRIP1, PALB2 and CHEK2) are known to have an increased risk for this dis-
ease (9, 10). An estimated 20% of breast cancer is explained, at least in part, 
by inherited genetic factors. Known, high-risk genes account for a relatively 
small proportion of this excess risk (approximately 5-10%) (11). The obvious 
implication of these findings is that additional susceptibility genes do exist 
(12).
Whether the polygenic model can also explain the disease in a number of 
extended families in which breast cancer clusters in 3-4 generations contin-
ues to be debated. Some argue that there must still be some unknown, rare, 
highly penetrant mutations accounting for breast cancer cases in such high-
risk families (9). However, others have argued that the polygenic model is the 
best fitting model to account for the residual familial aggregation of breast 
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cancer after excluding the known high-penetrance mutations (13, 14). Under 
this model, susceptibility to breast cancer is conferred by a large number of 
genetic variants which combine additively or multiplicatively, resulting in a 
range of susceptibilities in the population (15). The risk associated with each 
one of these is small, but as the effects are believed to be dose-dependent (16), 
a woman with several susceptibility alleles is at a higher risk. There have been 
multiple large-scale searches for genes involved in the susceptibility to breast 
cancer using association studies. The discovery of these new genes may allow 
for better risk prediction.
The most powerful approach to identify these low risk variants is through 
association studies. These studies test the frequency of genetic variants in 
(breast cancer) cases and controls (10) and are convenient because they do not 
require high-risk families, as does linkage analysis. The power to detect alleles 
of moderate effect is much larger for association than linkage studies (17). 
So far, the large majority of studies focused on candidate genes, chosen by 
investigators because of their potential role in carcinogenesis (12). The find-
ings from these studies have often been difficult to replicate. There have been 
a large number of explanations for this. The estimate of the first published 
statistically significant studies on a genetic association is probably often in-
flated (18). Some other issues to take into consideration is that there is a bias 
towards publishing significant findings and the more extreme a finding is the 
more likely it is to be published (publication bias). Further, researchers may 
not even submit negative findings for publication (selective reporting bias) 
(19). Other problems that have hampered association studies of candidate 
genes are small study size, a limited number of markers used to character-
ize the gene, failure to adjust for multiple testing and lack of replication of 
findings. These factors rendered studies largely underpowered (20). Recently, 
five new susceptibility loci were identified using a relatively new approach, 
genome-wide association (FGFR2, TNRC9, MAP3K1, an unknown locus 
at chromosome 8q and LSP1). Although genome-wide association does not 
differ from candidate gene studies technically, the scale of genotyping with 
100,000’s of SNPs in large series of patients and adequately numbers of size-
able replication studies has proven to be successful. The major difference with 
a candidate gene study is that no assumptions are made of genes and their 
functions Three out of the four new genes (FGFR2, MAP3K1 and TNRC9) 
are involved in control of cell growth and signaling, and LSP1 is involved in 
β cell signaling (21). The SNP (rs13281615) located on chromosome 8q is 
correlated with SNPs in a 110 kb LD block that contains no known genes 
(21). The basis of this association, therefore, remains unknown, but the SNP 
is approximately 130 kb proximal to rs16901979, a SNP recently shown to be 
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associated with prostate cancer (22-24). The odds ratios associated with these 
five variants range from 1.23 to 1.63. These findings are based on analyses 
performed in 21860 cases and 22578 controls. Although the effect of the 
single genes is small, when combined, the relative risk of disease will likely 
increase, perhaps to the extent that it would allow a useful tool for risk predic-
tion (15).
It has been suggested that a combination of these SNPs and others may be 
useful for screening purposes. The current surveillance program in The Neth-
erlands for women with a strong familiar or genetic predisposition consists 
of a clinical breast examination every six months, annual mammography and 
instructions for breast self-examinations (25). Screening is started five years 
prior to the earliest age of diagnosis in the family. MRI screening has been 
suggested particularly in young women (25). Also in the USA, MRI is par-
ticularly recommended for women with a high risk of breast cancer (>25%) 
who are under the age of 40 years. One may argue that, if we combine the 
tests of different genes, this may yield a new criteria for inclusion of women in 
MRI screening (26). However, as is the case with the Mendelian genes known 
to date, only a relatively small proportion of the women will carry all risk al-
leles of a sufficient number of risk variants to be at sufficiently increased risk. 
For most carriers, the risk may be rather modestly increased.
In this thesis, we followed a classical association approach in which we tar-
geted candidate genes, which, given their function, have a high probability to 
be involved in breast cancer. We targeted functional variants, which are known 
to influence protein levels theoretically. This allowed us also to quantify the 
effect of the proteins encoded by the genes (27). This approach is referred also 
to as Mendelian Randomization. The basic idea is that studies of proteins in 
disorders with a long induction period are often confounded. Further, due 
to the disease process, protein levels in the serum and tissue may change. 
Basically, by studying functional variants in genes we are using these as proxy 
for life time exposure to the protein at the tissue level, since DNA variants do 
not change, these studies will be less prone to confounding than conventional 
risk-factor epidemiology (27). We targeted several protein systems involved in 
the risk of disease. These included TGF-β1, IGF-I, ACE and AGT. Also, we 
investigated the interleukin-6 protein, which was previously implicated in the 
prognosis of breast cancer. We did this because it is plausible to assume that a 
polymorphism which predisposes to low Il-6 levels could increase the risk of 
breast cancer by decreasing immunological response to this disease (28).
All studies presented in this thesis were carried out as part of the Rot-
terdam study; a population based follow-up study of determinants of diseases 
in the elderly. All inhabitants of Ommoord, a suburb of Rotterdam, aged 55 
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years or older, were invited to participate; 7983 agreed (78.1%). The design 
of the study was previously described (29). Participants’ informed consent was 
obtained and the Medical Ethics Committee of the Erasmus Medical Center 
approved the study. Below, we summarize the findings.
8.2 Renin angiotensin system (RAS) polymorphisms
Besides its important role in homeostasis, angiotensin II, the main effector 
of RAS, was recently identified as an angiogenic and growth promoter agent 
(30). This molecule is converted from angiotensin I by the actions of the 
angiotensin-converting enzyme (ACE); ACE levels are genetically determined 
predominantly by a 287 bp Alu insertion/deletion (I/D) polymorphism lo-
cated in intron 16 (D carriers possessing higher ACE levels) (31). In Chapter 
2 we evaluated this variant and the risk of breast cancer and found that DD 
genotype carriers had an odds ratio (OR) = 1.86 (95% confidence interval 
(CI): 1.06-3.27, p = 0.03), compared with II carriers, for breast cancer risk. 
This association remained significant when additionally adjusting for parity 
(OR = 1.79; 95% CI: 1.06-3.27, p-value = 0.03), smoking (OR = 1.83; 95% 
CI: 1.04-3.21, p-value = 0.03) and BMI (OR = 2.06; 95% CI: 1.14-3.71, 
p-value = 0.02). The possibility that this is, in fact, a true finding is high, 
since several biological studies have demonstrated that angiotensin II acts as 
a growth promoter in normal and breast cancer cells through phospholipase 
C activation (32, 33). These findings are an independent replication of the 
results shown by Koh et al (34).
In Chapter 3 we analyze the relation of two polymorphisms in two genes 
of the RAS. While Angiotensin II has growth promoting activities and it me-
diates these through the Angiotensin II type I receptor (AGTR1) (33), Angio-
tensinogen (AGT) has antiproliferative properties (35). Due to these distinct 
properties of different members (of the same pathway) on cell proliferation, 
the relationship between AGT and breast cancer risk remained to be clarified. 
We chose two common polymorphisms that had been already associated with 
angiotensinogen plasma levels and hypertension (AGT M235T) (36) and 
with myocardial infarction (AGTR1 C573T) (37).
We found that MM carriers of the M235T angiotensinogen polymorphism 
(those who would have less circulating angiotensinogen) had an OR of 1.4 
(95% CI: 1.1-1.9) for breast cancer, against T allele carriers. This effect was 
maintained at all ages independently of well-known risk factors. On the other 
hand, there was no difference in risk among the different genotypes of the 
AGTR1 C573T variant. Our study was the first one to assess the relationship 
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between these two polymorphisms and the susceptibility to breast cancer. It 
is plausible to assume that an increase in AGT could hypothetically lead to 
an increase in angiotensin II which is a potent growth factor, but this might 
not be necessarily the case (35), therefore, as AGT has been associated to 
decrease growth promotion it would be plausible to assume that decreased 
levels of this molecule increase the risk for breast cancer. On the other hand, 
even though the C allele of the C573T variant in the AGTR1 gene has been 
found to be significantly more frequent in cases of myocardial infarction (37), 
and microalbuminuria in hypertensive patients (38), results have been rather 
inconsistent for this variant (39). Still, we believe that subsequent studies 
should be necessary to further investigate if these polymorphisms are truly 
involved or not in the pathogenesis of breast cancer.
8.3 Cytokine Polymorphisms
Breast cancer tumorigenesis is a complex process involving not only growth 
of the primary tumor but also communication with surrounding tissues and 
cells (40). It has been proven that stromal cells can promote the growth of 
most carcinomas including breast cancer through the secretion of molecules 
such as cytokines (41).
Chapter 4 presents a study on an IL-6 gene variant. The G-174C polymor-
phism in this gene had previously been studied in the context of prognosis in 
breast cancer (28, 42, 43), whereas, only one article had analyzed this variant 
in association to breast cancer risk and reported a relationship between the 
C allele, which is linked to lower IL-6 levels, and an increased risk for breast 
cancer (44). We found that in fact, carriers of the C allele had an increased 
risk, though not statistically significant, for breast cancer, when compared to 
non-carriers (OR=1.24, 95% 0.8-1.9,p=0.3) when taking into consideration 
all available cases (both prevalent and incident), an effect also seen in the sepa-
rate groups. Since cytokines are potent stimulators of the immune system, it 
would be plausible to assume that a polymorphism predisposing to low IL-6 
levels could increase the risk of breast cancer by decreasing immunological 
response to this disease (28).
In Chapter 5, we studied the relationship between the Leu10Pro variant 
in the TGF β1 gene and breast cancer in postmenopausal women. The study 
of this polymorphism has been of particular interest since TGF β1 has been 
shown to have a dual role in carcinogenesis. It acts as a tumor suppressor in-
hibiting epithelial cell proliferation in early stages and as a tumor promoter in 
later stages of carcinogenesis (45). In this gene, a T29C transition that results 
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in a Leu10Pro substitution in the signal peptide sequence of this gene has 
been found to regulate circulating levels of TGF-β1. Individuals homozygotes 
for proline have been found to have increased serum levels of TGF-β1 (46). 
We found that the incidence of breast cancer in carriers of at least one proline 
allele was statistically higher (p= 0.04) than in non-carriers, OR= 1.4 (95% 
CI = 1.1-2.0), this effect that was independent of well-known risk factors such 
as HRT and BMI.
TGF-β1 is a cytokine that has been linked to both tumor inhibition (47) 
and growth promotion (45) at different stages of the carcinogenic process 
in breast tissue. Since we found that women with the allele associated with 
higher levels of TGF-β1 have an increased risk for breast cancer, it is plausible 
to assume, that breast epithelial cells prone to oncogenesis, rapidly exceed the 
tumor suppressor properties of TGF-β1.
8.4 Insulin-like growth factor I (IGF-I) polymorphism
Chapter 6 describes the association analysis between the IGF-I CAn repeat 
polymorphism in the regulatory region of IGF-I and breast cancer morbidity. 
IGF-I is a paracrine and autocrine growth factor that is secreted by many 
tissues and has been implicated in tumor growth and metastasis (48). A CAn 
repeat in the gene’s promoter region has been associated with plasma IGF-I 
levels (49). The association between this variant and breast cancer remains 
unclear after a series of case-control studies, for this reason, a nested case-
control study was performed along with a meta-analysis of published data 
on this association. The result of a disease-free survival analysis adjusting 
for age at menopause, BMI, and WHR yielded a hazards ratio (HR) = 0.85 
(95%CI= 0.52-1.39) for CA19 heterozygotes versus CA19 homozygote carriers 
and a HR = 0.95 (95%CI= 0.56-1.62) for CA19 non-carriers against CA19 
homozygote carriers. When pooling heterozygotes and homozygous for the 
CA19 repeat and compared them vs. the non-carriers, we obtained an HR of 
0.97 (95% CI= 0.59-1.58). On the other hand, the meta-analysis produced a 
pooled OR=1.05 (95% CI=0.95-1.17) for CA19 heterozygous carriers versus 
CA19 homozygous carriers, and OR=1.26 (95% CI=0.87-1.82) for CA19 non-
carriers versus CA19 homozygous carriers, in contrast to the results found in 
our study. The fact that high heterogeneity was found in the analysis renders 
the interpretation of the results to be difficult. However, the estimates found 
in both analyses are not significant, suggesting that this polymorphism is not 
likely to be associated with breast cancer risk.
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8.5 Estrogen receptor 1 (ESR1) polymorphisms
Chapter 7 presents an association study between two well-studied polymor-
phisms in the ESR1 gene and the risk of breast cancer in postmenopausal 
women. This receptor is of particular interest to breast cancer susceptibility 
since it is probably the most important mediator of hormonal response in es-
trogen-sensitive tissues such as the breast (50) and plays a crucial role in breast 
growth and differentiation as well as in the development of cancer (51). The 
two most studied variants in the ESR1 gene are the PvuII and XbaI polymor-
phisms in intron 1 (52, 53). These two variants have been studied in relation 
to breast cancer susceptibility (50, 52, 54, 55) leading to contradicting results. 
It is important to clarify that the P (C) and X (G) allele carriers of this gene 
have been correlated with high bone mineral density and height in a study 
performed in our population, thus suggesting that carriers of these alleles have 
a stronger estrogenic activity (56). We carried out a logistic regression analysis 
adjusting for age at entry, age at menopause, BMI, WHR and HRT for both 
polymorphisms separately. We used the TT and AA genotypes as our refer-
ence categories in the analyses and found no significant differences in risk for 
breast cancer among carriers of the different genotypes of the PvuII or XbaI 
polymorphisms in the ESR1 gene. Furthermore, in order to evaluate our data 
together with those in the literature, we performed meta-analyses. Using the 
random effects model we did not find any difference in risk between XbaI and 
PvuII genotypes. The XbaI and PvuII polymorphisms are situated in intron 1 
and their functionality has not yet been demonstrated. Moreover, it has been 
suggested their effects could be the result of high linkage disequilibrium with 
functional variants that affect sensitivity to estrogen (57).
8.6  Preliminary results from genome-wide linkage 
analysis
Linkage studies have been the mainstay of geneticists and epidemiologists 
for localizing susceptibility genes for breast cancer for a long time. In linkage 
analysis cosegragation of a marker and a trait is examined. This approach has 
been successful in the identification of BRCA1 in 1990 by Hall et al (58) and 
BRCA2 in 1995 by Wooster et al (59). Previously, in 1984 Skolnick et al (60) 
found evidence for linkage on chromosome 9q34 (LOD score= 3.0). Sugges-
tive evidence for linkage were found on chromosome 13q21 (LOD=2.76) 
(61), 10q23.32-q25.3 (LOD=2.34), 12q14-q21. 19p13, 3.q12 (LOD=2.10), 
17p13 (LOD=1.5) (62) and 8p12-p22 (LOD=2.04) (63). The only LOD 
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score higher than 3.0, was found on chromosome 2q32 (LOD=3.20) (62). 
Most of these findings have not been replicated consistently.
Yet as discussed earlier, there still are extended families in which the disease 
segregates as a dominant trait. We therefore carried out a preliminary link-
age analysis (not presented in this thesis) using a dominant and a recessive 
model using a series of 10 distantly related patients from a genetically isolated 
population of the south of The Netherlands. This population was constituted 
in the middle of the 18th century by a limited number of founders and we 
recently started the ERF (Erasmus Rucphen Family) cohort study, which is 
concentrating on unraveling genes underlying quantitative trait variation in 
humans. At present, information has been collected on ~2600 participants 
who comprise the last 4-5 generations of a single large pedigree, connecting 
9800 individuals (64). We identified a total of 21 female breast cancer patients 
through the clinical files of the general practitioners working in this popu-
lation. Only patients with a confirming pathological exam of breast cancer 
diagnosis were considered cases. Out of these, 10 patients were characterized 
with 6009 SNPs spread across the genome. In the linkage analysis, the highest 
LOD score found was 0.399 for markers rs2835626 through rs2835649 on 
chromosome 21, using the recessive model. These findings are disappointing, 
but in this first stage of the analysis only 10 out of 21 breast cancer cases were 
genotyped. The final conclusion awaits the genotyping of all patients.
8.7 Conclusions
In the last decade there has been a dramatic rise in the number of published 
association studies reporting the relationship between SNPs and the risk of 
breast cancer (15). Findings have not always been consistent and few new dis-
ease loci have been identified unequivocally (65). The main reason for these 
results is that much larger studies than those carried out to date are needed to 
provide sufficient statistical power to assess small associations, especially those 
that involve several genetic variants or between genetic and environmental 
factors (66). In order to solve such a dilemma, either larger studies or pooled 
analyses have to be carried out, such is the case of the breast cancer associa-
tion consortium (BCAC) that found two polymorphisms (CASP8 D302H 
and TGFβ1 L10P) to be associated to a significant decreased (in the case of 
the CASP8 variant) or increased (in the case of the TGFβ1) risk for breast 
neoplasia (67).
The search for these low-penetrance variants has centered increasingly to 
association studies, where the genotype frequencies of candidate genes are 
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compared in cases and controls or using the transmission disequilibrium test 
(TDT) or allied tests. In order to detect a variant with a frequency of 0.01, 
conferring a twofold increase in risk would require about 10 000 affected 
trios, or in the case of association analysis, 500 unselected cases and 500 con-
trols. This clearly shows that the case-control design is most powerful, also 
when compared to the TDT.
In this thesis, the association studies were carried out in a large follow-
up study, which comprised more than 7000 people. Unfortunately, a limited 
number of breast cancer cases (N=308) have been detected so far and it can 
therefore be argued that our studies have been underpowered. The power cal-
culation above shows that the Rotterdam Study is underpowered to detect 
such rare variants, despite the large numbers of controls available (308 cases 
and ~3651 controls) (15). In the Rotterdam study we can only detect common 
variants. According to our power calculations for the interleukin 6 polymor-
phism for instance, our study had enough power (β=0.8) to detect an odds 
ratio of 1.25 or above per risk allele of the IL-6 G-174C variant (risk allele 
frequency= 42%, 308 cases and 3651 controls). If we consider the power of 
the Rotterdam study in view of the use of Mendelian Randomization, where 
one takes the gene as an approximate for the effect of the protein, the power 
is further limited (β=0.05) to show an effect of the protein on the disease risk. 
This makes it difficult to interpret the negative findings and, according to the 
principle of Mendelian Randomization to exclude the role of this protein in 
the risk of breast cancer.
Nevertheless, the number of patients studied in the Rotterdam Study al-
lowed us to detect three statistically significant associations (ACE I/D, TGFβ1 
Leu10Pro and AGT M235T), one of these (TGFβ1 Leu10Pro) has been 
subsequently found to be associated by the BCAC (67). Although one may 
debate whether this approach is able to detect proteins with a minimum effect 
and whether we can appropriately quantify the effect, our approach makes 
it plausible that the ACE, AGT and TGFβ1 proteins do play a role in breast 
cancer risk. In particular the findings on AGT are of interest as they suggest 
that whereas angiotensin II has a growth promoting effect, angiotensinogen 
has the opposite effect. Whether or not the other two proteins encoded by the 
IL-6 and AGTR genes are indeed associated with an increased risk for breast 
cancer will need further studies given the low statistical power to detect minor 
effects.
We further evaluated if there was a multiplicative effect between our sig-
nificantly associated variants. When studying the joint effect of genes pair 
wise, we found an interaction between the TGF-β1 Leu10Pro and the AGT 
M235T polymorphisms (p for interaction=0.009), suggesting that the addi-
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tive and multiplicative models do not hold. We did not find evidence for in-
teraction or a multiplicative effect between AGT and ACE (p for interaction 
= 0.91) and ACE and TGFβ1 (p for interaction = 0.12). Tables 1 and 2 show 
the observed and expected odds ratios assuming a multiplicative model. As 
can be seen from the tables the ORs assuming a multiplicative model deviate 
substantially from that observed. This suggests that the multiplicative model 
does not hold. However, as can be seen from the tables, the numbers are too 
small to draw a definitive conclusion.
In relation to the other variants studied in this thesis, it seems clear that 
the IGF-I CAn repeat, ESR1 XbaI and PvuII variants are not associated with 
breast cancer risk as demonstrated by our analyses and also the meta-analyses 
carried out. For the AGTR1 C573T and the IL-6 G-174C polymorphisms 
the situation is less clear and the final conclusion awaits larger case series to 
rule out their involvement in breast carcinogenesis given the low statistical 
power to detect protein effect. Nevertheless, this does not imply that these 
proteins are not relevant
Table 1- Multiplicative model for AGT and ACE genes
AGT* ACE** N Cases N Controls Exp OR Obs OR
0 0 36 637 ref ref
0 1 67 1471 NA 0.83
0 2 46 837 NA 1.00
1 0 01 121 NA 0.15
1 1 16 282 0.12 1.00
1 2 11 141 0.15 1.40
*AGT 0 = TT and MT genotypes, AGT 1 = MM genotype
**ACE 0 = II genotype, ACE 1 = ID genotype and ACE 2 = DD genotype
Table 2- Multiplicative model for TGFβ1 and ACE genes
TGFβ1* ACE** N cases N Controls Exp OR Obs OR
0 0 11 292 ref ref
0 1 33 696 NA 1.13
0 2 16 384 NA 1.14
1 0 26 434 NA 1.16
1 1 46 982 1.31 1.13
1 2 40 547 1.32 1.26
*TGFβ1 0 = Leu/Leu genotype, TGFβ1 1 = Leu/Pro and Pro/Pro genotypes
**ACE 0 = II genotype, ACE 1 = ID genotype and ACE 2 = DD genotype
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8.8 Future research
An interesting question to address further is whether the large number of 
small risk genes act according to a multiplicative or additive model. Another 
interesting venue is to follow the genome-wide association approach as per-
formed by Easton et al, which suggested that a multiplicative model fitted the 
data better (21). They found five novel independent loci that exhibited strong 
and consistent evidence for association with breast cancer (P<10-7). Four of 
these contain plausible causative genes (FGFR2, TNRC9, MAP3K1 and 
LSP1) (21). Although only one of them (FGFR2) had a clear prior relevance 
to breast cancer from molecular studies (21). Also interaction studies between 
genetic variants are of interest. Recently an interaction between IGF1 and ESR 
was suggested. We tested for a possible interaction and found no evidence for 
a synergistic effect (p for interaction = 0.56). Studies of additive or multi-
plicative effects of variants with small effects and of interaction require large 
samples, which could be addressed by meta-analysis. An important problem 
to address remains publication bias, i.e. studies with significant findings are 
more likely to be published than those with non-significant results. One may 
argue that it is relevant to publish both significant and non-significant results. 
The latter may be of interest scientifically, in particular in a meta-analysis as 
we have followed this strategy in chapters 6 and 7.
From a clinical perspective, an interesting question is to study polymor-
phisms in relation to breast cancer survival. The studies of van Gils et al (68) 
for instance looked at both breast cancer risk and prognosis in relation to the 
5-alpha reductase gene. While this gene might not be associated with the risk 
for breast cancer, it could influence survival or be related to prognostic fac-
tors (68). Studies by Piersma also reveal associations between genetic variants 
and prognostic factors such as nodal involvement and larger tumor size to 
carriers of the Luteinizing hormone receptor (LHR) insLQ allele (69). These 
studies could not be replicated in the Rotterdam study because the number 
of deaths due to breast cancer was very small, in particular for those with an 
early onset (premenopausal) of breast cancer for whom survival was found 
to be associated to the insLQ variant in the LHR gene and the16Ser allele of 
the Gonadotropin-releasing hormone (GnRH) gene (70, 71). Neither did we 
have information on tumor characteristics from our patients.
There is an ongoing debate whether it is likely that there will be a large 
number of additional genes yet to be discovered with high penetrance compa-
rable to that of BRCA1 and BRCA2. On the one hand it has been argued that 
most of the residual familial aggregation for breast cancer must be due to a 
polygenic model, where common alleles acting together in a dose-dependent 
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manner account for the majority of familiar breast cancer cases (12). One of 
the best-known breast cancer geneticists, prof Dr. MC King argues that there 
must still be some uncommon highly penetrant mutations accounting for 
those breast cancer cases in high-risk families, and the reason why these have 
not been found yet is due to high genetic heterogeneity in between high-risk 
families. Another explanation may be that there is an interaction of a small 
number of genes (2 or 3) underlying the strong familial aggregation is smaller 
pedigrees. Although risks are very high for carriers, these genes only account 
for 5-10% of breast cancer cases in the population (72). Yet, clinically, these 
carriers may be most interesting because of the high risk and therefore eligible 
screening. The same argument holds for carriers of multiple low risk variants. 
Ironically, most likely the combination of genetic variants will yield high-risk 
groups eligible for screening, which, most likely also concern small subgroups 
(73).
Finally, it is also important to take into account the many environmental 
factors that do play an important role in the etiology of this common disease 
(1). Studies evaluating the incidence of breast cancer in Asian migrants into 
western countries show that these migrants do tend to adjust to the incidence 
of their new homeland within two or three generations, therefore pointing to 
life style factors influencing the etiology of breast cancer (74). Also studies of 
interaction of genes with smoking and other toxic exposures such as alcohol 
may be of interest. Studying the interactions between such factors and certain 
relevant genetic variants could yield valuable information in the area of breast 
cancer research.
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Breast cancer is the most common malignancy in women in the western world 
and family history of this disease is the most important risk factor. After the 
discovery of BRCA1 and BRCA2 through linkage analysis and positional clon-
ing, other rare mutations in eight genes are considered susceptibility genes 
for breast cancer and these are: TP53, PTEN, LKB1, ATM, NBS1, RAD50, 
BRIP1, PALB2 and CHEK2. Segregation analyses have suggested that a poly-
genic model, may account for much of the residual genetic component of 
breast cancer susceptibility and the most powerful approach to find such vari-
ants is through case-control association studies. All studies in this thesis were 
based on the Rotterdam study, a population-based cohort study, including 
7983 participants 55 year old or older.
Chapter 1 presents a general introduction where methods for finding new 
susceptibility loci for breast cancer are discussed.
Chapter 2 describes the association between the angiotensin-converting 
enzyme (ACE) insertion/deletion polymorphism and the risk of breast cancer. 
We found that women who are homozygous carriers of the deletion allele, 
who have higher levels of circulating ACE, are at an increased risk for breast 
cancer. This is an interesting finding since ACE converts angiotensin I to 
angiotensin II, which has been found to be a potent growth factor in many 
tissues including the breast.
In Chapter 3 two polymorphisms in two genes of the renin-angiotensin 
system, the angiotensinogen (AGT) M235T and angiotensin type 1 receptor 
(AGTR1) C573T were analyzed in order to clarify their relationship to breast 
cancer risk. We found that women who were MM carriers of the M235T 
AGT polymorphism were at an increased risk for postmenopausal breast can-
cer. This is of particular interest since the M allele has been correlated to lower 
plasma levels of angiotensinogen. On the other hand, the C573T AGTR1-
variant does not seem to influence breast cancer risk. These findings suggest 
that whereas angiotensin II has growth promoting activities, angiotensinogen 
has the opposite effects, as shown by previous molecular studies.
In Chapter 4, we describe the association of interleukin 6 (Il-6) G (-174) 
C variant and the risk of breast cancer. We found a non-statistically significant 
increased risk of breast cancer for C allele carriers, which have been linked to 
lower levels of Il-6.
Chapter 5 focused on the relationship between the L10P variant in the 
transforming growth factor β1 (TGF β1) gene and breast cancer in postmeno-
pausal women. We found that women homozygotes for proline (who have 
been found to have increased serum levels of TGF-β1) are at an increased risk 
for postmenopausal breast cancer.
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In Chapter 6 we analyzed the association between the IGF-I CAn repeat 
polymorphism and breast cancer morbidity. The association between this 
variant and breast cancer has remained unclear after a series of case-control 
studies, for this reason, a nested case-control study was performed along with 
a meta-analysis of published data on this association. Neither of these analyses 
found an association between this variant and the risk of breast cancer.
Finally Chapter 7 presents an association study between two well-studied 
polymorphisms in the ESR1 gene and the risk of breast cancer in postmeno-
pausal women. These are the PvuII and XbaI polymorphisms. In the associa-
tion studies and meta-analyses we found no statistically significant association 
between the different PvuII or XbaI genotypes and breast cancer.
In the general discussion shown in Chapter 8, we discuss the main find-
ings including a preliminary genome-wide linkage analysis, which was not 
presented in the thesis. The chapter shows that genetic variation in different 
pathways of carcinogenesis such as growth promotion and neovascularization 
could play an important role in the pathogenesis of breast cancer. Never-
theless, because such common variants account only for modestly increased 
risks for the disease more research in this area along as the implementation of 
genome-wide association analysis comprising the genotyping of large num-
bers of cases and controls.
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Samenvatting
Borstkanker is de meest voorkomende kwaadaardige tumor bij Westerse vrou-
wen. De belangrijkste risicofactor voor borstkanker is een familiegeschiedenis 
van borstkanker. De borstkankergenen BRCA1 en BRCA2 werden ontdekt met 
behulp van linkage analyse en positionele klonering. Andere zeldzame muta-
ties in acht genen worden gezien als predisponerende genen voor kanker. Dit 
betreffen: TP53, PTEN, LKB1, ATM, NBS1, RAD50, BRIP1, and CHEK2. 
Al deze genen zorgen voor een sterk verhoogd risico op het krijgen van borst-
kanker, maar komen maar weinig voor in de algemene bevolking en daar-
door is slechts een klein deel van het totale aantal borstkankerpatiënten toe 
te schrijven aan deze genen. Segregatie analyses suggereerden dat een model 
waarin meerdere genen betrokken zijn, een groot deel van de resterende ge-
netische component van borstkanker predispositie voor zijn rekening neemt. 
Patiënt-controle associatie studies zijn de krachtigste benaderingen om dit 
soort varianten te vinden. Alle onderzoeken in dit proefschrift zijn gebaseerd 
op de Erasmus Rotterdam Gezondheid Onderzoek Studie (ERGO), een be-
volkings cohort onderzoek, waarin 7983 deelnemers werden van 55 jaar of 
ouder worden vervolgd n de tijd.
Hoofdstuk 1 is een algemene inleiding waarin methoden om nieuwe pre-
disponerende loci voor het vinden van borstkanker worden beschreven.
Hoofdstuk 2 beschrijft de associatie tussen het angiotensine-converterende 
enzym (ACE) insertie/deletie polymorfisme en de kans op borstkanker. Wij 
ontdekten dat vrouwen die homozygote dragers zijn van het deletie allel en 
hogere spiegels circulerend ACE hebben, een verhoogde kans hebben op het 
krijgen van borstkanker. Dit is een interessante bevinding, omdat ACE angi-
otensine I omzet in angiotensine II, dat weer gevonden is als een mogelijke 
groeifactor in verschillende weefsels, waaronder borstweetsel.
In Hoofdstuk 3 worden de resultaten weergegeven van een studie waarin 
twee polymorfismen in twee genen van het renine-angiotensine systeem, het 
angiotensinogeen (AGT) M235T en angiotensine type 1 receptor (AGTR1) 
C573T werden geanalyseerd om hun relatie tot het borstkankerrisico op te 
helderen. Wij vonden dat vrouwen die MM dragers waren van het M235T 
AGT polymorfisme een verhoogde kans hebben op het krijgen van post-
menopausale borstkanker. Dit heeft in het bijzonder de belangstelling gewekt 
omdat het M allel is gerelateerd aan lagere plasmaspiegels van het angitensi-
nogeen. Echter, de variant C573T AGTR1 lijkt het borstkankerrisico niet te 
beïnvloeden.
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In Hoofdstuk 4 beschrijven we de associatie tussen de interleukin 6 (IL-6) 
G (-174) C variant en de kans op het krijgen van borstkanker. We vonden 
een niet-statistisch significant verhoogd risico voor borstkanker voor C allel 
dragers, wat gerelateerd is aan lagere spiegels van IL-6.
Hoofdstuk 5 richt zich op de relatie tussen de L10P variant in het trans-
formerende groeifactor β1 (TGF β1) gen en borstkanker in post-menopausale 
vrouwen. We vonden dat vrouwen die homozygoot zijn voor proline (zij 
hebben een verhoogd serumlevel TGF β1) een verhoogd risico hebben op 
postmenopausale borstkanker.
In Hoofdstuk 6 wordt de associatie tussen het IGF-I CAn herhalings-po-
lymorfisme en borstkankermorbiditeit beschreven. De associatie tussen deze 
variant en borstkankerrisico is onduidelijk gebleven na een serie case-control 
onderzoeken. Daarom voerden we nested patiënt-controle onderzoek en een 
meta-analyse van gepubliceerde data die deze associatie betreffen uit. Geen 
van deze analyses toonden een associatie tussen deze variant en het risico van 
borstkanker aan.
Tenslotte beschrijft Hoofdstuk 7 de resultaten van een onderzoek naar 
associatie tussen twee uitvoering-bestudeerde polymorfismen in het ESR1 gen 
en het risico voor borstkanker in postmenopausale vrouwen; de PvuII and 
XbaI polymorfismen. In de associatie studies en de meta-analyses vonden we 
geen statistisch significante associatie tussen de verschillende PvuII en XbaI 
genotypen en borstkanker.
In de algemene discussie in Hoofdstuk 8 bediscussiëren we de belang-
rijkste bevindingen samen en worden oof de resultaten van een preliminaire 
genoom-brede linkage analyse gepresenteerd. Het hoofdstuk laat zien dat ge-
netische variatie in verschillende carcinogenese-pathways, zoals groeipromotie 
en neovascularisatie een rol spleen in de pathogenese van borstkanker. Omdat 
dit soort veel voorkomende varianten slechts een bescheiden deel van de risi-
coverhoging voor borstkanker kunnen verklaren is meer onderzoek op dit vlak 
erg belangrijk, zoals de implementatie van genoom-brede associatie analyse, 
waarin grote aantallen patiënten en controlepersonen bestudeerd worden.
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Resumen
El cáncer de mama es la neoplasia mas común en mujeres del mundo occiden-
tal y la historia familiar de esta enfermedad es el factor de riesgo mas impor-
tante. Después del descubrimiento de BRCA1 y BRCA2 a través de analyses de 
ligamiento y la clonación posicional, otros ocho genes han sido considerados 
como genes de susceptibilidad para el cancer de mama y estos son: TP53, 
PTEN, LKB1, ATM, NBS1, RAD50, BRIP1, PALB2 and CHEK2. Recientes 
analyses de segregación han sugerido que el modelo poligénico podria ser 
responsible de la mayoría del componente genético residual y la manera mas 
robusta de para encontrar tales variantes es a través de estudios de asocia-
ción caso-control. Todos los estudios en esta tésis fueron llevados a cabo en 
el Rotterdam study, un estudio poblacional de cohortes, el cual incluye 7983 
participantes de 55 años de edad en adelante.
El capítulo 1 presenta la introducción en general donde los metodos para 
encontrar nuevos genes de susceptibilidad para el cancer de mama son ex-
puestos.
El capítulo 2 describe la asociación entre el polimorfismo de inserción-
delección del gen de la enzima convertidora de angiotensina (ECA) y el riesgo 
de cáncer de mama. Se encontró que las mujeres homozigotas para el allelo 
de delección, quienes tienen niveles circulates de ECA elevados, tienen un 
riesgo incrementado de desarrollar cancer de mama. Este hallazgo no deja de 
ser interesante, ya que la ECA convierte la angiotensina I en angiotensina I, 
la cual es un potente factor de crecimiento en muchos tejidos incluyendo el 
mamario.
En el capítulo 3, dos polymorfismos en dos genes del sistema renina-
angiotensina, la variante M235T en el gen del angiotensinogeno (AGT) y la 
variants C573T en el gen del receptor tipo 1 de angiotensina (AGTR1) fueron 
analizados para poder aclarar su relación con el cancer de mama. Se encontró 
que las mujeres quienes eran portadoras del genotipo MM depolimorfimos 
M235T en el gen de AGT tenian un riesgo incrementado de cancer de mama. 
Este hallazgo es de interés ya que el allelo M ha sido correlacionado con ni-
veles bajos de AGT plasmático. Por otra parte, la variante C573 en el gen del 
AGTR1 no influenciaría el riesgo de cancer de mama. Estos hallazgos sugie-
ren que mientras la angiotensina II promueve el crecimiento cellular, el AGT 
tiene efectos opuestos, como se muestra en estudios moleculares previos.
En el capítulo 4, describimos la asociación de la variants G (-174) C en el 
gen de la interleukina 6 (Il-6) y el riesgo de cancer de mama. Apreciamos que 
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había un aumento de riesgo de cancer de mama (aunque estadísticamente no 
significativo) para las portadoras del allelo C, el cual ha sido relacionado con 
niveles plasmáticos disminuidos de Il-6.
El capítulo 5 presenta la relación entre el polimorfismo L10P en el gen del 
factor de crecimiento transformador tipo β1 (TGF β1) y el cancer de mama 
en mujeres post-menopáusicas. Se aprecia que las mujeres homozygotes para 
prolina (quienes tienen niveles séricos elevados de TGF-β1) tienen el rieso 
incrementado para el cancer de mama en la post-menopáusia.
En el capítulo 6 se analizó la asociación entre la variante CAn en el gen del 
factor de crecimiento similar a la insulina (IGF-I) y la morbilidad de cancer de 
mama. La asociacióm entre este polimorfismo y el cancer de mama no ha sido 
esclarecida después de una serie de estudios de caso-control, por esta razon, un 
estudio de tipo caso-control nidificado fue llevado a cabo conjuntamente con 
un meta-análisis de estudios previamente publicados sobre esta acosiación. 
Ninguno de estos analyses encontraron alguna asociación entre esta variante y 
el riesgo de cancer de mama.
Finalmente el capítulo 7 presenta un estudio de asociación entre dos po-
limorfismos bastante estudiados en el gen del receptor de estrogeno tipo 1 
(ESR1) y el riesgo de cancer de mama en la post-menopáusia. Estas son las 
variants PvuII y XbaI. En los estudios de asociación y los meta-análises no se 
encontró ninguna asociación estadísticamente significativa entre estos poli-
morfismos y el cancer de mama.
En la discusión general presentada en el capítulo 8, se discuten los hallaz-
gos principales incluyendo un analisis de ligamiento preliminary, el cual no 
fue presentado en la tésis. Los resultados indican que la variación genética en 
diferentes vías relacionadas con los procesos carcinogénicos tales como lo son 
la promoción del crecimiento y la neovascularización podrían jugar un rol 
importante en la patogénesis del cáncer de mama
Sin embargo, debido a que variants tan communes son responsables de 
solo un modesto aumento en el riesgo de esta enfermedad, mas investigación 
en esta area es necesaria como a la vez lo es la implementación de análisis de 
asociación que incluya todo el genoma (genome-wide association analysis), 
genotipando a su vez grandes números de casos y controles.
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